



Email: dcoidcwa@gmail.com

Website: www.dcoiwa.com

H.Q.: 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S.) India 500072. Phone 8121296397, 8094357800, 9977187574

Monthly Newsletter



For circulation among DCOIWA members only

In collaboration with



The Health Master

Published on 1st day of every month

Happy New Year
2026



Union Health and Family Welfare Minister J.P. Nadda praised the efforts of the Haryana Government

Haryana Minister Rao, senior officials, met with Union Health and Family Welfare Minister J.P. Nadda at his office in New Delhi. The important meeting reviewed the progress of key health programs in Haryana and discussed the support expected from the central government. The Union Minister praised the Haryana government's efforts in the health sector.

Emphasis on "TB-free Haryana"

The meeting commended the state's performance under the TB Free India/TB Free Haryana campaign. The Union Minister recommended further strengthening the Nikshay Poshan Yojana, increasing the participation of Nikshay Mitras, and expanding X-ray screening coverage. A 100-day TB campaign will be relaunched in February, with the active participation of MPs, MLAs, district committees, and deputy commissioners.

Improved availability of medicines and diagnostic services

Haryana's Essential Medicines List (EDL) includes more medicines than the national list. The availability of essential medicines in public

Health Aarti Singh along with department

health institutions was found to be over 90 percent, and total molecule availability was above 80 percent, which the Union Minister praised.

Regarding diagnostic services, 13 types of tests are available at the sub-health center level, while 108 of the 134 listed tests are available at district hospitals. Community Health Centers (CHCs) and Primary Health Centers (PHCs) also offer a large number of diagnostic services. It was suggested that these services be further strengthened through a hub-and-spoke model.

Discussion on human resources and budget structure

The meeting emphasized increasing the availability of medical specialists and



J P Nadda



Arti Singh Rao

(Continued on page 16)



23

Editorial Board

Editor-in-Chief:

Rakesh Dahiya

Co-Editor:

P. K. Jaggi

Editorial Board:

A. Manikandan IAS

Dr. A. Ram Kishan (CDSCO)

N.V. Raghu Ram (Karnataka)

Dr. Amal Kumar (Bihar)

Naripen Kumar Goyal (Haryana)

Dr. Arvind. H. Zala (Gujarat)

Dr. Ram Chandra Besra (Jharkhand)

Mrs. K Limasenla Longchar (Nagaland)

Mijom Lollen (Arunachal Pradesh)

Piyush Jiaswal (Chhatisgarh)

Shabir Ahmad Pandit (J&K)

Dr. BR Jagashetty (Karnataka)

Dr. Swapnil Patil (Delhi)

Pooran Chand (Uttar Pradesh)

Murali Krishnan MP (Tamil Nadu)

Dr. Jayesh V. Patel (Gujarat)

Advisory Board:

G. Koteswar Rao (National President)

Baldev Choudhry (Hon. Gen Secretary)

Lalit Kr. Goel (Founder member)



**D
C
O
I
W
A

N
E
W
S**



**EDITORIAL****Rakesh Dahiya****Editor-in-Chief
DCOIWA Newsletter****A New Dawn: Stepping into
2026 with Vision and Unity**

As the first light of January 1, 2026, breaks across the horizon, it brings with it more than just a new calendar year. It brings a sense of renewed purpose and a fresh canvas for our collective mission. It is my distinct honor to welcome you to the **23rd Edition of the DCOIWA Newsletter**. On behalf of the entire editorial team, I wish every member of the Drugs Control Officer (I) Welfare Association a healthy, prosperous, and transformative **Happy New Year 2026**.

This edition is a milestone, not just in its numbering, but in the depth of technical expertise and regional updates it carries. As we celebrate our growth, we also lean into a moment of mindfulness. Our President shares a poignant message today, bridging the leadership vision for 2026 with the serenity of **World Meditation Day**. In a profession as high-stakes and demanding as drug regulation, finding that internal

balance is not just a luxury—it is a necessity for sound judgment and public service.

Deep Dives into Regulation and Science

This month, we have curated exclusive articles that tackle the complexities of our evolving landscape. We dive into the practicalities of the **Homoeopathic medicine manufacturing license procedure**, a sector seeing significant growth. We also explore the critical legal boundaries of **"Borderline Products,"** dissecting the thin lines that separate drugs from devices, foods, and nutraceuticals—a constant challenge for the modern regulator.

Furthermore, we are proud to feature:

- **Ketamine Regulations:** A comprehensive look at its classification in India by Lalit Kr. Goel.
- **Precision Medicine:** A fascinating comparative study on the regulatory future of personalized care between the U.S. and India.
- **DCOIWA Webinar Series-10:** A summary of our vital discussion on Drug-Drug interactions from a regulatory lens.

(Continued on page 4)

**EDITORIAL**

(Continued from page 3)

From the Field: News and Milestones

The spirit of DCOIWA is felt most strongly in our chapters and on the ground. This month, we cover the **Odisha Chapter's General Body Meeting** and celebrate the accolades received by the **Haryana Government** from Union Health Minister J.P. Nadda.

From the bustling corridors of the **74th IPC in Bengaluru** to the strategic "Chintan Shivir" in Chandigarh, our members are at the heart of the national pharmaceutical dialogue. We also take a moment to applaud **Mrs. Navdeep Kaur** on her recent achievements and honor our colleagues transitioning into new chapters of life with our **retirement tributes**.

Operational Excellence and Alerts

As always, this newsletter serves as your technical handbook. We have included:

- **Technical Notes:** Insights on **Revised Schedule M** and a comprehensive guide to **Medical Device Schedules**.
- **Public Safety:** Critical details on **Not of Standard Quality (NSQ) drugs** from November 2025, alongside the latest drug alerts and recalls.

Updates: The most recent notifications regarding **DPCO 2013, NDPS drugs, and Banned Substances**.

A Shared Journey

Regulation is often a thankless job, performed in the quiet spaces between manufacturing and consumption. Yet, as evidenced by the rigorous work of FDAs in **Telangana, Andhra Pradesh, Puducherry, Tamil Nadu, and Chhattisgarh**, our vigilance is the bedrock of public health.

As you flip through these pages—from the "Laughter Dose" that lightens our burden to the complex FAQs on pharmaceutical standards—remember that this newsletter is a reflection of *you*. Your dedication, your integrity, and your expertise are what keep the spirit of DCOIWA alive.

Here is to a year of sharpening our skills, strengthening our bonds, and ensuring the safety of every citizen.

Happy Reading and a Grand 2026 to all!





Happy New Year 2026

2026

HAPPY NEW YEAR





23

New Year Wishes from President



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

- Organizing Secretary:**
Mr. Rakesh Dahiya
Cell: 99116 00019, Haryana
- Vice-Presidents:**
Mr. Lalit Kumar Goel
Cell: 70567 02999, Haryana
Dr. M. Dhillip Kumar
Cell: 9840071715, Tamilnadu
Mr. D. R. Gahane
Cell: 98928 32289, Maharashtra
Mr. V. D. Dobarja
Cell: 98790 60666, Gujarat
Dr. A. Ramkishan
Cell: 63057 50926, CDSCO
Dr. Manish Kapoor
Cell: -9418081270 - Himachal Pradesh
Mrs. Kanchan Sinha
Cell: 9774548986 - Tripura
- Joint Secretaries:**
Mr. Rajkumar V. Zadbuke
Cell: 9892827738 - Maharashtra
Dr. S. Umesh
Cell: 94480 54321 - Karnataka
Mr. Pooran Chand
Cell: 9760366100 - Uttar Pradesh
Mrs. Dipika Chauhan
Cell: 7990351251 - Gujarat
Mr. Chandan Kumar Giri
Cell: 8895478543 - Odisha
Mr. Amit Kumar Bansal
Cell: 9198463261 - Uttar Pradesh
Mr. Biswajit Talukdar
Cell: 7086084833 - Assam
- Treasurer:**
Dr. Parmanand Verma
Cell: 9977177574 - Chhattisgarh
- EC Members:**
Dr. E. Ananda Kirouchenane
Cell: 9443959680 - Puducherry
Mr. Venkatesh Sinari
Cell: 9850608501 - Goa
Mrs. Garima Sharma
Cell: 9418086497 - Himachal Pradesh
Mr. M. N. Sridhar
Cell: 94441 17139 - Tamilnadu
Mr. Ashutosh Kumar Chaube
Cell: 9415632071 - Uttar Pradesh
Dr. Mahalakshmy .R
Cell: 9497004156 - Kerala
Dr. Zaffer Ahmad
Cell: 7298009092 - Jammu & Kashmir
Mr. Iarap T. D. Toi
Cell: 9233323204 - Meghalaya
Mr. Ibom Ete
Cell: 8414819858 - Arunachal Pradesh
Mr. Neeraj Kumar
Cell: 9458900286 - Uttarakhand
Dr. Mrinal Kanti Sarkar
Cell: 8974822360 - Tripura
Mr. Tapan Choudhry
Cell: 9230610226 - West Bangal



Date: 1st January 2026
Place: Hyderabad

Dear Colleagues, Members and Well-Wishers of DCOIWA,

As we stand at the threshold of a New Year, it is a moment of reflection, gratitude, and renewed hope. The year 2025 now draws to a close, leaving behind memories of dedication, challenges, achievements, and collective growth.

On behalf of the Drugs Control Officers India Welfare Association (DCOIWA), I extend my heartfelt appreciation to each one of you for your unwavering commitment to public health, regulatory excellence, and professional integrity. The efforts and sacrifices made by Drugs Control Officers across the nation during 2025 have significantly strengthened our healthcare system and upheld the trust of the public.

As we bid a respectful farewell to 2025, we also embrace 2026 with optimism and determination. The New Year brings fresh opportunities to further enhance regulatory standards, strengthen unity among officers, and work with renewed vigor for the welfare of our fraternity and society at large.

May 2026 be a year filled with good health, professional success, personal happiness, and collective progress. Let us move forward together with confidence, compassion, and a shared vision for a stronger and more resilient regulatory framework.

I wish you and your families a Happy, Prosperous, and Peaceful New Year 2026.

With warm regards and best wishes,

G. Koteswar Rao
National President
Drugs Control Officers India Welfare Association (DCOIWA)



H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800, 9977177574.



President Note

1



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

- Organizing Secretary: Mr. Rakesh Dahiya
Vice-Presidents: Mr. Lalit Kumar Goel, Dr. M. Dhilip Kumar, Mr. D. R. Gahane, Mr. V. D. Dobaria, Dr. A. Ramkishan, Dr. Manish Kapoor, Mrs. Kanchan Sinha
Joint Secretaries: Mr. Rajkumar V. Zadbuke, Dr. S. Umesh, Mr. Pooran Chand, Mrs. Dipika Chauhan, Mr. Chandan Kumar Giri, Mr. Amit Kumar Bansal, Mr. Biswajit Talukdar
Treasurer: Dr. Parmanand Verma
EC Members: Dr. E. Ananda Kirouchenane, Mr. Venkatesh Sinari, Mrs. Garima Sharma, Mr. M. N. Sridhar, Mr. Ashutosh Kumar Chaube, Dr. Mahalakshmy .R, Dr. Zaffer Ahmad, Mr. Irap T. D. Toi, Mr. Ibom Ete, Mr. Neeraj Kumar, Dr. Mrinal Kanti Sarkar, Mr. Tapan Choudhry

Lt. No. DCOIWA/151225/05

Date: 31st December 2025
Place: Hyderabad.

PRESIDENT'S NOTE:

Drugs Control Officers India Welfare Association (DCOIWA)
For the Year Ending 31st December 2025

Dear Esteemed Members,

As we conclude the year 2025, I take this opportunity to present the President's Report of the Drugs Control Officers India Welfare Association (DCOIWA). The year has been one of purposeful engagement, professional growth, and renewed commitment towards strengthening the drug regulatory system in India while safeguarding the welfare and dignity of Drugs Control Officers across the country.

Strengthening Professional Capacity

One of the key priorities of DCOIWA during 2025 has been capacity building and continuous professional development. The Association successfully organized and supported several training programs, workshops, and knowledge-sharing initiatives aimed at upgrading the technical and regulatory skills of Drugs Control Officers and laboratory analysts.

A notable achievement was the conduct of intensive training programs for State Drug Testing Laboratory analysts, including specialized programs conducted in coordination with industry subject matter experts. These initiatives contributed significantly to enhancing analytical competence, regulatory awareness, and adoption of best practices in drug testing and enforcement.

Engagement with Regulatory Leadership

DCOIWA continued its constructive engagement with senior regulatory authorities at the national and state levels. Meaningful interactions with the Drugs Controller General of India (DCGI) and other key stakeholders helped place important issues concerning regulatory strengthening, enforcement challenges, and officer welfare on the policy agenda.

Special emphasis was laid on advocating for:

- Strengthening of drug and cosmetic regulatory enforcement
Creation of dedicated cadres and infrastructure
Recognition of the vital role played by Drugs Control Officers in ensuring public health and patient safety

The Association's views and recommendations were positively received, reflecting DCOIWA's growing credibility as a responsible professional body.

Advocacy and Welfare Initiatives

The welfare of our members remained central to all activities of DCOIWA in 2025. The Association actively addressed service-related issues, professional challenges, and concerns affecting Drugs Control Officers across various states. Through representations, consultations, and dialogue, DCOIWA continued to stand firmly in support of its members.

H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.



President Note



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

- Organizing Secretary: Mr. Rakesh Dahiya
Vice-Presidents: Mr. Lalit Kumar Goel, Dr. M. Dhillip Kumar, Mr. D. R. Gahane, Mr. V. D. Dobaria, Dr. A. Ramkishan, Dr. Manish Kapoor, Mrs. Kanchan Sinha
Joint Secretaries: Mr. Rajkumar V. Zadbuke, Dr. S. Umesh, Mr. Pooran Chand, Mrs. Dipika Chauhan, Mr. Chandan Kumar Giri, Mr. Amit Kumar Bansal, Mr. Biswajit Talukdar
Treasurer: Dr. Parmanand Verma
EC Members: Dr. E. Ananda Kirouchenane, Mr. Venkatesh Sinari, Mrs. Garima Sharma, Mr. M. N. Sridhar, Mr. Ashutosh Kumar Chaube, Dr. Mahalakshmy .R, Dr. Zaffer Ahmad, Mr. Irap T. D. Toi, Mr. Ibom Ete, Mr. Neeraj Kumar, Dr. Mrinal Kanti Sarkar, Mr. Tapan Choudhry

We also strengthened internal communication and unity among members, reinforcing the Association's foundational principles of solidarity, integrity, and service.

National Presence and Outreach

DCOIWA expanded its national footprint during the year through increased participation in seminars, conferences, training programs, and public health initiatives.

Efforts were made to foster collaboration between regulators, academia, and industry, ensuring that regulatory objectives are aligned with scientific advancement and ethical practices.

Acknowledgement and Gratitude

I sincerely acknowledge the dedicated efforts of the office bearers, executive committee members, state units, and every DCOIWA member who contributed selflessly to the Association's progress during 2025.

Way Forward

As we move into the coming year, DCOIWA remains committed to:

- Enhancing professional excellence
Protecting the interests and welfare of Drugs Control Officers
Supporting robust and transparent regulatory systems
Serving public health with integrity and dedication

Together, we shall continue to work towards a stronger, more empowered regulatory fraternity that commands respect and delivers trust to the nation.

With warm regards and best wishes for the new year 2026.

[Signature]

G. Koteswar Rao
National President
Drugs Control Officers India Welfare Association (DCOIWA)



Procedure to obtain license for manufacturing of Homoeopathic medicines

1

[Rakesh Dahiya](#)

Editor-in-Chief,
DCOIWA News
Organising Secretary,
DCOIWA
Asstt. State Drugs Controller,
FDA Haryana



How to obtain manufacturing license for Homeopathic medicines


Documents required

For obtaining manufacturing license for Homeopathic medicines, the list of documents required is provided below. Download the pdf file and prepare the documents accordingly.

[Documents-required-for-obtaining-license-for-Mfg-of-Homeopathic-Medicines](#)

Procedure for grant

PROCEDURE



Procedure for obtaining manufacturing license for Homeopathic medicines. Download the pdf file for more detail and prepare the documents accordingly.

[Procedure-for-obtaining-Homeopathic-mfg-license](#)

Application form

Download the pdf file and prepare the Form accordingly and submit the required fee.

Form-24 C

Download the below pdf files for various Forms which suits your requirement

[Form-24C](#)

Click below link to download the fee structure of all types of drug licenses

[License fee structure for all licenses](#)

Click below link to download the requirement for the manufacturing of Drugs, Cosmetics, Homoeopathic and Blood Centre

[Area requirement for](#)

(Continued on page 10)

Procedure to obtain license for manufacturing of Homoeopathic medicines

2

(Continued from page 9)

[manufacturing](#)

Schedule M-I

[Schedule-M-I](#)

Submit your application (Online and / or hard copy) to State Drugs Controller / Licensing Authority of your area after completing all the required documents.

Note: Requirements of some of documents and procedure for submission of application may vary from State to State

License conditions

Conditions of licenses is to be maintained after obtaining the required manufacturing license for Homeopathic medicines. Download the pdf file for ready reference.

[License-Conditions-for-manufacturing-of-Homoeopathic-Medicines](#)

Procedure for renewal

Procedure for submission of license renewal fee. Download the pdf file for more detail and prepare the documents accordingly.

[Procedure-for-License-renewal](#)



List of Laboratory Instruments

We have provided list of laboratory instruments, click below link to explore:

[List of Laboratory Instruments for Pharma & Cosmetics Industry](#)

Compiled by:

[Rakesh Dahiya](#)

Asstt. State Drugs Controller

[FDA Haryana](#)

[Click here for more articles of the Author](#)

Legal Anatomy of Borderline Products in India: Drug, Device, Cosmetics, Food/Nutraceuticals

1

Dr. Amal Kumar

M.Pharm, Ph.D, LLB

Drugs Control Administration

Bihar



Borderline products are those that sit at the interface of drug, medical device, food/nutraceutical, and cosmetics definitions, so their classification depends less on the dosage form and more on intent, claims, composition, and mode of action.

Core legal interpretation of definitions-

“Drug”

Intended for diagnosis, treatment, mitigation, or prevention of disease, or to affect structure/function of body; includes many devices notified as “drug” and certain topical preparations.

“Medical device”

Instrument/apparatus/software etc. intended for diagnosis, prevention, monitoring, treatment, or alleviation of disease, whose principal intended action is not achieved by pharmacological, immunological, or metabolic means.

“Food / nutraceutical” (FSSAI):

Article of food, including health supplements, functional foods, and nutraceuticals, meant to supplement diet; may carry structure/function or health-support claims but cannot claim cure/treatment of disease and must respect RDA limits and positive lists.

“Cosmetic”

Product applied to human body for cleansing, beautifying, promoting attractiveness, or altering appearance, without therapeutic or prophylactic claims or systemic action.

Regulatory “tests” used for borderline classification

Regulators and courts typically apply a set of practical tests across categories.

Primary purpose / “care vs cure” test

- If principal function is cure/treatment/prevention of a disease or disorder, product tends toward drug/medical device.
- If principal function is hygiene, beautification, or general wellness/care with no curative intent, product tends toward cosmetic/food.

2. Claim-based test

- Explicit therapeutic claims (“treats acne”, “prevents osteoporosis”, “controls blood sugar in diabetes”) → drug or device.
- General wellness or structure/function claims (“supports immunity”, “helps maintain joint health”, “enhances glow”) with compliant composition → food or cosmetic.

3. Composition and dose

- Scheduled APIs, high-potency hormones, antibiotics, corticosteroids, etc. → drug, regardless of cosmetic-like presentation.
- Nutrients/botanicals within FSSAI limits and on approved lists → food/nutraceutical; exceeding limits or using non-approved actives pushes toward drug.

4. Mode of action

- Primarily pharmacological/immunological/metabolic action → drug.
- Primarily physical or mechanical action (barrier, pressure, filtration, simple lubrication) → medical device.
- Superficial local effect on appearance only → cosmetic.

5. Presentation, use-pattern, and professional supervision

- Prescription use, hospital setting, or prescriber-driven product (e.g., dermatology cream like Moisturex) strongly indicates medicament.
- General retail, self-care positioning suggests cosmetic/food, provided other tests also align that

(Continued on page 12)

Legal Anatomy of Borderline Products in India: Drug, Device, Cosmetics, Food/Nutraceuticals

2

(Continued from page 11)

way.

Typical borderline interfaces

Drug–cosmetic interface

Examples

- Anti-dandruff shampoo with ketoconazole: cosmetic format but therapeutic anti-fungal claim → treated as *drug*.

- Moisturizing cream prescribed for ichthyosis with pharmacologically active ingredients (Moisturex): held to be *medicament*, not cosmetic, by Supreme Court using “cure vs care” test.

- High-SPF sunscreen with claims like “prevents sunburn and skin damage in photosensitive conditions” tends toward *drug*, while a basic SPF product making beautifying/appearance-related claims tends toward *cosmetic*.

Key regulators/route

- If classified as drug → Central Licensing + State Licensing under Drugs & Cosmetics Act/Rules (now integrated with Cosmetics Rules 2020 where relevant).

- If cosmetic → licensing/registration under cosmetic provisions, BIS standards, labelling restrictions.

Drug–nutraceutical/food interface

Examples

- Vitamin D, B12, iron, etc. at dietary levels in chewable tablets or gummies, labelled “supplement” with RDA-compliant doses and no disease claims → food/nutraceutical (FSSAI).

- Same ingredients at pharmacological doses, in prescription packs, intended for treatment of deficiency anaemia or osteoporosis → drug.

- Botanicals like curcumin or plant sterols used within FSSAI limits for “supports heart health” → *nutraceutical*; used in high-dose capsules with claims such as “lowers LDL in hyperlipidaemia” → *drug*.

Key regulators/route

- Food/nutraceutical → FSSAI licensing, compliance with nutraceutical regulations, RDA



limits, and claim restrictions.

- Drug → new drug / fixed-dose combination or generic route, plus GMP under Schedule M, PV obligations etc.

Drug–medical device interface

Examples

- Pre-filled heparin syringe: often regulated as *drug–device combination*, with classification based on principal intended action (pharmacological vs mechanical).

- Wound dressings with only physical barrier → *medical device*; if impregnated with silver sulfadiazine at medicinal dose, classification shifts towards *drug/combination*.

- Contact lenses vs lubricating ophthalmic drops: lenses (mechanical correction) → *device*; drops with pharmacologically active ingredients → *drug*.

Key regulators/route

- Devices → MDR 2017, risk-based Class A–D, licensing via CDSCO/State SLAs and notified bodies.

- Drug or combo → Drugs & Cosmetics Act; CDSCO determines the lead framework case by case.

Cosmetic–device hybrids

Examples

- Micro-needling rollers, dermal rollers sold for skin rejuvenation → usually *Class B medical

(Continued on page 13)

Legal Anatomy of Borderline Products in India: Drug, Device, Cosmetics, Food/Nutraceuticals

3

(Continued from page 12)

devices* (mechanical action).

- LED facial masks for acne or photorejuvenation → medical devices if intended for treatment of acne/photo-damage; beauty gadgets if restricted to mild cosmetic claims.



Key legal tests used in India for borderline classification (drug vs cosmetic vs nutraceutical/food vs others) revolve around purpose, claims, composition, mode of action, and regulatory licensing history.

1. “Cure or care” / primary function test

- The Supreme Court in the *Moisturex* line of cases held that the deciding question is whether the product mainly ****cures/treats**** a condition (medicament) or mainly ***cares/beautifies*** (cosmetic).
- Even if sold OTC, a product can still be a medicament if:
 - It is prescribed by doctors for specific conditions, and
 - Contains ingredients with curative properties, even in small quantities.

2. Claim-based test (labelling, ads, trade dress)

- Therapeutic or disease-related claims like “treats”, “cures”, “controls”, “prevents” → strong indicator of ***drug/medicament*** classification, not cosmetic or simple food.

- Under FSSAI’s nutraceutical and advertising regulations, food/health supplements must avoid disease cure/treatment claims; crossing this line pushes them into ****drug**** territory.

3. Composition, potency, and RDA compliance

- Use of pharmacologically active substances (e.g., corticosteroids, antibiotics, strong keratolytics) even at low levels supports ***medicament*** classification, not cosmetic.
- For nutraceuticals, FSSAI has directed that products exceeding ***RDA limits*** or using non-approved ingredients should not be sold under

food licences and instead require drug licence.

4. Mode of action and product category

- If the principal intended action is ***pharmacological, immunological or metabolic***, the product tends toward ***drug/medicament***.

- Where the principal action is purely ***cosmetic (appearance)*** or ***nutritional (dietary support)*** within approved limits, it remains cosmetic/food; and where action is mainly ***physical or mechanical***, it leans towards ***medical device***.

5. Consumer perception and usage pattern

- Courts consider how an ***average consumer*** perceives the product: is it bought and used to treat a condition on doctor’s advice, or as a routine beauty/hygiene item.
- Evidence such as prescription use, presence in pharmacy vs general grocery channels, and how the trade understands the product supports classification as medicament versus cosmetic/food.

6. Licensing history and regulatory treatment

- If the manufacturer itself has taken a ***drug licence*** and complied with drug labelling/requirements, that fact weighs heavily towards medicament classification.
- Conversely, products licensed under FSSAI as health supplements but later found to exceed RDA or make drug-like claims may be directed to shift to drug licensing, reflecting that food law was being improperly used.

Together, these tests are applied cumulatively; no single factor is conclusive, but primary purpose, intended use, claims, and composition usually carry the greatest weight in Indian borderline classification decisions.

Source: Dr. Amal Kumar

Regulation and the Future of Precision Medicine: A U.S.–India Comparison

1

Dr. Jayesh V Patel

M.Pharm, Ph.D,



1. Introduction: The value of Regulation in Precision Medicine.

Precision medicine is no longer a research-based ideology but a more and more integrated part of the currently used healthcare. Genomics, biomarker-directed treatment, and computational technologies (including artificial intelligence, AI) have made personalized approaches to disease risk assessment, diagnosis, and treatment a possibility.

Nonetheless, since the technology of precision medicine is leaving the strict research settings and entering the mainstream clinical setting, it has become apparent that scientific innovation is not enough to promote the safe, effective, and equitable application of these technologies.

Precision medicine technologies are radically different because they are comparable to traditional pharmaceuticals. Genomic tests are continually changing, as additional variants are discovered, AI-assisted clinical applications could be enhanced by refining algorithms, and numerous precision medicine interventions can involve a combination of diagnostics, therapeutic and computer-aided decision-making.

Such features impose high requirements on the regulation mechanisms, which in the past were intended to work with stable products with well-established signs.

Consequently, regulation has not only become an oversight mechanism but also a key factor in determining whether precision medicine can be adopted on a large scale in a responsible manner.

2. Regulatory Framework of Precision Medicine in the US.

The US has created one of the most developed regulatory landscapes in relation to precision medicine. Under its regulatory control over the use of medical devices and drugs, the U.S. Food and Drug Administration (FDA) regulates genomics-based

diagnostics, companion diagnostics, and software-based medical products using existing pathways.

The FDA has been making guidance on next-generation sequencing technologies, real-world evidence use, and software as a medical device (SaMD), which is an acknowledgement of the fact that traditional regulatory models need to be changed to fit data-driven and ever-changing technologies.

Nevertheless, even with this fairly developed framework, there are still regulatory issues.

Regulation of AI-enabled clinical decision-support systems is a dynamic field, especially regarding the updates to the algorithms, transparency, and monitoring of their performance over time.

Besides, the regulatory tasks that apply directly to precision medicine, including the approval of diagnostics and therapeutics, data protection, and post-market surveillance, fall across various federal agencies.

This institutional ambiguity may pose coordination difficulties, particularly with regard to products combining genomic testing, artificial intelligence-based analysis, and therapeutic decision-making in a single clinical process.

3. Indian Regulatory Environment of Precision Medicine.

India is a different regulatory environment that is characterised by growing scientific strength and continuous regulatory evolution.

There is increasing interest in the use of precision medicine methods, as the country has initiated a number of national programs in areas of genomics, population health research, and digital health infrastructure.

Such activities make India a significant player in the research and innovation of genomic and personalized healthcare in the world.

Nonetheless, there are few regulatory frameworks that are specifically applied to precision medicine.

Regulation of genetic testing, medical devices, and AI-controllable diagnostic tools is mostly performed in the framework of the current regulations, including the Medical Device Rules and the recommendations of

(Continued on page 15)

Regulation and the Future of Precision Medicine: A U.S.–India Comparison

2

(Continued from page 14)

national health and research organisations. Recent data protection laws have enhanced governance of health and personal data, though this model applies specifically to genomic or precision medicine data. Consequently, the challenges of clinical validity criteria of genetic testing, algorithmic responsibility, and formalised post-market oversight of AI-based instruments are currently not comprehensively and medicinally focused significantly regulated.

The same regulatory ambiguity can raise confusion among healthcare providers, industry stakeholders, and patients despite the further increase in the pace of innovation activity.

4. Comparative Regulatory Problems: Innovation, Trust and Equity.

The case study of the United States and India reveals a similar regulatory problem, as the need to balance innovation and trust by the population. Precision medicine is dependent on the gathering, saving, and processing of genomic and health information, which are both sensitive and highly personal.

Lack of regulatory certainty or inconsistent regulation can augment the possibility of information misuse, the lack of trust, and even aggravate the presence of health inequities, especially those populations that are already underrepresented in genomic studies.

The U.S. regulatory system focuses on flexibility and evidence-based regulation and has to cope with rising complexity and inter-agency coordination issues.

India, in its turn, has the primary challenge of establishing consistent regulatory frameworks that can possibly facilitate precision medicine innovation and still provide patient protection in an uneven and resource-adaptable system of healthcare.

Regulation is central in both of these contexts to influence the experiences of perception, adoption and maintenance of precision medicine.

5. Regulation as an Instigating Responsible Precision Medicine.

Regulation cannot be considered to be a barrier to precision medicine.

Instead, it is a precondition of ethical integrity, clinical reliability and equal access.



Efficient regulatory tools should also focus on data privacy, informed consent, analytical and clinical validity, algorithmic bias and transparency, although they should be sufficiently adaptable to address scientific and technological innovations.

In the US, further regulatory creation may be aimed at enhancing the inter-agency coordination and the enforcement of control over medical systems based on AI.

Key areas in India, such as enhancing regulatory guidance relevant to precision medicine, standardisation between agencies, and coordinating innovation efforts with ethical and clinical protection, are viewed as priorities.

6. Conclusion

Due to the growth of precision medicine in the world market, regulatory systems will significantly influence the ultimate outcome of such a phenomenon in society.

The comparison of the United States and India shows that scientific progress is necessary but not enough in itself.

Precision medicine is a threat to a lopsided implementation and lack of accountability without sound, adaptive, and ethically based regulatory frameworks.

Moving on, regulation will have to grow as a more proactive role rather than a mainly reactive one, and, in that way, it will be able to ensure the safety, reliability, and patient-centeredness of precision medicine as well as offer innovation opportunities.

Source: Dr. Jayesh V Patel

Union Health and Family Welfare Minister J.P. Nadda.....



Smt. Arti Singh Rao, Health Minister, Haryana, Sh. Sudhir Rajpal IAS, ACS, Health, Haryana Govt, Dr. Manoj Kumar IAS, Commissioner, FDA Haryana, Dr. Virender Yadav, Mr. Lalit Kr. Goel, State Drugs Controller, FDA Haryana and other Officers

(Continued from page 1)

streamlining their deployment. Currently, Haryana spends approximately 70 percent of its health budget on salaries. Rational recruitment and planning were recommended to bring this figure down to 50 percent in a phased manner, in line with other states.

Drug Supply Portal and FDA Reform

The state was advised to fully implement the drug availability portal down to the sub-health center level to provide information on drug availability to the general public. Instructions were given to expedite the pending mapping work.

It was informed in the meeting that deputation based appointments have been made on key posts under the Food and Drug Administration (FDA) and laboratories are being set up for quality control.

Focus on medical education and PPP

Information was provided about the start of operations of a medical and nursing college in Bhiwani. The Union Minister advised increasing UG and PG medical seats in Haryana. He also urged the government to coordinate with the PPP Cell established by the central government and explore partnership opportunities in diagnostic and other services.

State demands placed before the Central Government

In the meeting, the Haryana government placed several important demands before the Centre,

including a dedicated TB hospital in Hisar, uninterrupted supply of CBNAAT cartridges, HPV vaccine for cervical cancer prevention, PET/SPECT facilities for cancer and NCD management, extension of 15th Finance Commission support, targeted infrastructure support for South Haryana, additional ambulances, expansion of Neonatal Care Units (SNCU), mammography, audiology clinics, special disease clinics, fibroscan facilities at the district level and an integrated IT platform for all health programmes.

Appreciation of achievements

Union Minister J.P. Nadda specifically commended Haryana for reducing its maternal mortality rate (MMR) and infant mortality rate (IMR) and achieving over 400 percent full immunization coverage (FIC). At the end of the meeting, the Union Minister commended the Haryana government's efforts and assured the central government of all possible support to further strengthen the state's public health system.

On this occasion, Union Health Secretary Punya Salila Srivastava, Haryana Health and Family Welfare Minister Aarti Singh Rao, besides ACS of the department Sudhir Rajpal, Commissioner of Food and Drugs Administration Department Dr Manoj Kumar, Drugs Controller General of India Rajiv Singh Raghuvanshi, State Drugs Controller of Haryana Lalit Goyal, Director Health Services Dr Virendra Yadav and Joint Food Commissioner Prithvi Singh were also present.

Source: Newsam.in



23

Congratulations Mrs. Navdeep Kaur

1



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

Organizing Secretary:

Mr. Rakesh Dahiya
Cell: 99116 00019, Haryana

Vice-Presidents:

Mr. Lalit Kumar Goel
Cell: 70567 02999, Haryana

Dr. M. Dhillip Kumar
Cell: 9840071715, Tamilnadu

Mr. D. R. Gahane
Cell: 98928 32289, Maharashtra

Mr. V. D. Dobaría
Cell: 98790 60666, Gujarat

Dr. A. Ramkishan
Cell: 63057 50926, CDSCO

Dr. Manish Kapoor
Cell: -9418081270 - Himachal Pradesh

Mrs. Kanchan Sinha
Cell: 9774548986 - Tripura

Joint Secretaries:

Mr. Rajkumar V. Zadbuqe
Cell: 9892827738 - Maharashtra

Dr. S. Umesh
Cell: 94480 54321 - Karnataka

Mr. Pooran Chand
Cell: 9760366100 - Uttar Pradesh

Mrs. Dipika Chauhan
Cell: 7990351251 - Gujarat

Mr. Chandan Kumar Giri
Cell: 8895478543 - Odisha

Mr. Amit Kumar Bansal
Cell: 9198463261 - Uttar Pradesh

Mr. Biswajit Talukdar
Cell: 7086084833 - Assam

Treasurer:
Dr. Parmanand Verma
Cell: 9977177574 - Chhattisgarh

EC Members:

Dr. E. Ananda Kirouchenane
Cell: 9443959680 - Puduchery

Mr. Venkatesh Sinari
Cell: 9850608501 - Goa

Mrs. Garima Sharma
Cell: 9418086497 - Himachal Pradesh

Mr. M. N. Sridhar
Cell: 94441 17139 - Tamilnadu

Mr. Ashutosh Kumar Chaube
Cell: 9415632071 - Uttar Pradesh

Dr. Mahalakshmy .R
Cell: 9497004156 - Kerala

Dr. Zaffer Ahmad
Cell: 7298009092 - Jammu & Kashmir

Mr. Iarap T. D. Toi
Cell: 9233323204 - Meghalaya

Mr. Ibom Ete
Cell: 8414819858 - Arunachal Pradesh

Mr. Neeraj Kumar
Cell: 9458900286 - Uttarakhand

Dr. Mrinal Kanti Sarkar
Cell: 8974822360 - Tripura

Mr. Tapan Choudhry
Cell: 9230610226 - West Bangal

Date: 31st December 2025
Place: Hyderabad

To
Mrs. Navdeep Kaur
Drugs Control Officer
Fatehgarh Sahib,
Punjab

Dear Madam,

On behalf of the Drugs Control Officers India Welfare Association (DCOIWA), it gives me immense pride and pleasure to extend our heartfelt congratulations to you on being awarded 1st Runner-Up at "Mrs Supernational 2025", held on 2nd December 2025.

Your remarkable performance was further crowned with the prestigious titles of "Best National Costume Award" and "Mrs Global Ambassador", recognizing your outstanding confidence, grace, and brilliant presence throughout the finale week. These honors truly reflect your exceptional personality and global appeal.

Your journey of excellence did not begin this year alone. In 2024, you were crowned Mrs India 2024, which provided you the opportunity to represent India on an international platform. You once again made the nation proud by securing 1st Runner-Up at Mrs Supernational, becoming the first Indian woman to achieve such an international distinction. In addition, you brought further laurels to the country by winning the Best National Costume Award for India and the Mrs Global Ambassador title.

Your achievements have set a shining example that the sky is truly the limit. You have beautifully demonstrated the power, confidence, and capability of women. As a Drugs Control Officer, your success has not only inspired women across the country but has also brought immense pride to the entire Drugs Control fraternity.

As National President, and on behalf of DCOIWA, we once again congratulate you sincerely and look forward to witnessing many more milestones in all your future endeavors.

H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800, 9977177574.



Congratulations Mrs. Navdeep Kaur



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

- Organizing Secretary: Mr. Rakesh Dahiya
Vice-Presidents: Mr. Lalit Kumar Goel, Dr. M. Dhilip Kumar, Mr. D. R. Gahane, Mr. V. D. Dobarra, Dr. A. Ramkishan, Dr. Manish Kapoor
Joint Secretaries: Mr. Rajkumar V. Zadbuke, Dr. S. Umesh
Treasurer: Dr. Parmanand Verma
EC Members: Dr. E. Ananda Kirouchenane, Mr. Venkatesh Sinari, Mrs. Garima Sharma, Mr. M. N. Sridhar, Mr. Ashutosh Kumar Chaube, Dr. Mahalakshmy .R, Dr. Zaffer Ahmad, Mr. Irap T. D. Toi, Mr. Ibom Ete, Mr. Neeraj Kumar, Dr. Mrinal Kanti Sarkar, Mr. Tapan Choudhry

May God bless you with continued success, strength, and excellence.

Note: With due respect we are awarding honorary / complimentary membership to you in DCOIWA. Requested to accept the same.

With warm regards,

[Handwritten signature]

G. Koteswar Rao
National President
Drugs Control Officers India Welfare Association




H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.



23

DCOIWA Webinar Series-10

Drug-Drug interactions: A critical & Regulatory Perspective



Drugs Control Officers (I) Welfare Association & Indian Pharmacy Graduates' Association Telangana



Jointly Organising International Webinar

DCO(I)WA WEBINAR SERIES - 10



Chief Guest Dr. V. KALAISELVAN

Secretary-cum-Scientific Director, Indian Pharmacopoeia commission.



TOPIC : Drug: Drug Interactions A Clinical & Regulatory Perspective.

Key Note Speaker

Prof. Krishna R. Devarakonda

M.Pharm, Ph.D., FCP, AvH Fellow

Founder & Chief Scientific Officer

6-S Pharma Inc., Belle Mead, NJ. USA

ZOOM ID :

& PW :

On SATURDAY 3RD JANUARY 2026

Time:

7:00 - 8:00 pm

ISD



Dr. Parmanand Verma Chairman DCOIWA Webinar Wing +91 9977177574



Mr. Krishna Kumar Co Chairman DCOIWA Webinar Wing +91 9494129261



Mr. G. Koteswar Rao Advisor DCOIWA Webinar Wing +91 8121296397



Mr. Manmohan Taneja Advisor DCOIWA Webinar Wing +91 99909 36900

Click any where to read all the DCOIWA Newsletters



E-Newsletter

DCOIWA News

Drugs Control Officers (I) Welfare Association (Regd)



President message on World Meditation Day



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

- Organizing Secretary: Mr. Rakesh Dahiya
Vice-Presidents: Mr. Lalit Kumar Goel, Dr. M. Dhilip Kumar, Mr. D. R. Gahane, Mr. V. D. Dobaria, Dr. A. Ramkishan, Dr. Manish Kapoor, Mrs. Kanchan Sinha
Joint Secretaries: Mr. Rajkumar V. Zadbuke, Dr. S. Umesh, Mr. Pooran Chand, Mrs. Dipika Chauhan, Mr. Chandan Kumar Giri, Mr. Biswajit Talukdar
Treasurer: Dr. Parmanand Verma
EC Members: Dr. E. Ananda Kirouchenane, Mr. Venkatesh Sinari, Mrs. Garima Sharma, Mr. M. N. Sridhar, Mr. Ashutosh Kumar Chaube, Dr. Mahalakshmy .R, Dr. Zaffer Ahmad, Mr. Irap T. D. Toi, Mr. Ibom Ete, Mr. Neeraj Kumar, Dr. Mrinal Kanti Sarkar, Mr. Tapan Choudhry

Lt. No. DCOIWA/111225/04

Date: 12 December 2025
Place: Hyderabad

Dear Colleagues and Well-Wishers,

The United Nations has declared 21st December as World Meditation Day, a landmark initiative introduced in 2024. India has been honored as the Global Partner for this historic movement. This date holds deep significance as it marks the solstice—a time symbolizing natural transformation, renewal, and the shift from darkness to light across the world.

On 21st December 2025, more than one million people from around the globe will unite for a 20-minute meditation session at 8.00 pm. Guided by Kamalesh D Patel (Daaji), this heart-based meditation encourages us to journey inward and experience stillness, balance, and harmony. When millions of hearts come together with a shared intention, profound collective awakening becomes possible.

I warmly encourage all members, officers, and well-wishers of the Drugs Control Officers India Welfare Association (DCOIWA) to participate in this global moment of peace and inner strength.

Register now: https://meditationday.global/hi/

Let us join hands and hearts for a more conscious, compassionate, and peaceful world.

#Heartfulness #WorldMeditationDay #Meditation #Daaji

G. KOTESHWAR RAO
National President
Drugs Control Officers
India Welfare Association

BALDEV CHOUDHARY
National General Secretary

H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.



Contributions from DCOIWA to 74th IPC, Bengaluru



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President

Dr. HEMANT G. KOSHIA

Cell: 99784 05054 - Gujarat

President

G. KOTESHWAR RAO

Cell: 8121296397 - Telangana

General Secretary

BALDEV CHOUDHARY

Cell: 8094357800 - Rajasthan

Organizing Secretary:

Mr. Rakesh Dahiya

Cell: 99116 00019, Haryana

Vice-Presidents:

Mr. Lalit Kumar Goel

Cell: 70567 02999, Haryana

Dr. M. Dhilip Kumar

Cell: 9840071715, Tamilnadu

Mr. D. R. Gahane

Cell: 98928 32289, Maharashtra

Mr. V. D. Dobarla

Cell: 98790 60666, Gujarat

Dr. A. Ramkishan

Cell: 63057 50926, CDSCO

Dr. Manish Kapoor

Cell: -9418081270 - Himachal Pradesh

Mrs. Kanchan Sinha

Cell: 9774548986 - Tripura

Joint Secretaries:

Mr. Rajkumar V. Zadbuke

Cell: 9892827738 - Maharashtra

Dr. S. Umesh

Cell: 94480 54321 - Karnataka

Mr. Pooran Chand

Cell: 9760366100 - Uttar Pradesh

Mrs. Dipika Chauhan

Cell: 7990351251 - Gujarat

Mr. Chandan Kumar Giri

Cell: 8895478543 - Odisha

Mr. Amit Kumar Bansal

Cell: 9198463261 - Uttar Pradesh

Mr. Biswajit Talukdar

Cell: 7086084833 - Assam

Treasurer:

Dr. Parmanand Verma

Cell: 9977177574 - Chhattisgarh

EC Members:

Dr. E. Ananda Kirouchenane

Cell: 9443959680 - Puducherry

Mr. Venkatesh Sinari

Cell: 9850608501 - Goa

Mrs. Garima Sharma

Cell: 9418086497 - Himachal Pradesh

Mr. M. N. Sridhar

Cell: 94441 17139 - Tamilnadu

Mr. Ashutosh Kumar Chaube

Cell: 9415632071 - Uttar Pradesh

Dr. Mahalakshmy .R

Cell: 9497004156 - Kerala

Dr. Zaffer Ahmad

Cell: 7298009092 - Jammu & Kashmir

Mr. Irap T. D. Toi

Cell: 9233323204 - Meghalaya

Mr. Ibom Ete

Cell: 8414819858 - Arunachal Pradesh

Mr. Neeraj Kumar

Cell: 9458900286 - Uttarakhand

Dr. Mrinal Kanti Sarkar

Cell: 8974822360 - Tripura

Mr. Tapan Choudhry

Cell: 9230610226 - West Bangal

Lt. No. DCOIWA/191225/05

Date: 19 December 2025

Place: Bengaluru

To
Shri T. V. Narayana,
Secretary, IPCA

Respected Sir,

On behalf of the Drugs Control Officers India Welfare Association (DCOIWA), I extend our sincere gratitude to the Board Members of the 74th Indian Pharmaceutical Congress for graciously including DCOIWA as a Co-Host for this prestigious event.


In this regard, we are pleased to enclose herewith a cheque for Rs. 5.00 lakhs towards DCOIWA's contribution to the 74th Indian Pharmaceutical Congress.

We deeply value this association and assure you of our continuous cooperation and wholehearted support in all your future endeavors aimed at the advancement of the pharmaceutical profession and public health.

Thanking you once again.

Yours sincerely,

G. Koteswar Rao
National President
Drugs Control Officers India Welfare Association



H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.



General body meeting of DCOIWA Odisha Chapter



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

ODISHA CHAPTER

Email: dcoiwaodisha@gmail.com Website: www.dcoiwa.com

President

Smt. Mamina Pattnaik

Cell: 9437013646, LM - 1083

General Secretary

Mr. Rudra Narayan Sahu

Cell: 9337876809, LM - 346

Treasurer

Smt. Sunita Rani Patra

Cell: 94386 76209, LM -1084

Vice Presidents:

Harmohan Mohanty

Cell: 9437136217

Lalit Kumar Sahoo

Cell: 9437232661 - LM - 989

Joint Secretaries:

Debashis Kalo

Cell: 9439788348 - LM-995

Sangita Pattnayak

Cell: 7605930020

EC Members:

Rosalin Samal

Cell: 9777742147

Sukanta Sahu

Cell: 8904682241

Deepak Jena

Cell: 6296498189

Chinmay Jena

Cell: 7978534240 - LM-436

Priyanka Chakraborty

Cell: 9861137886 - LM-257

Harapriya Mallick

Cell: 9438739290

Jyoti Ranjan Panda

Cell: 9439365871 - 996

Sanjay Kumar Hansda

Cell: 9439368682, LM -1058

Satyabrata Giri

Cell: 9437695156, LM-1085

Date: 15 December 2025

Place: Bhubaneswar

Today, under the able leadership of Smt. Momina Patnayak, State Drugs Controller, Odisha, and in the esteemed presence of the National President and National General Secretary of DCOIWA, the General Body Meeting of the DCOIWA Odisha State Chapter was held at Bhubaneswar.

During the meeting, the new office bearers of the DCOIWA Odisha Chapter were unanimously elected, marking an important step towards strengthening the activities of the Association in the state.

The DCOIWA National Committee extends its heartfelt congratulations to all the newly elected office bearers and wishes them a successful and impactful tenure in serving the objectives of the Association and the welfare of Drugs Control Officers.



Address: Directorate of Drugs Control, Gajapati Nagar, Press Chowk, Near Sainik School, Bhubaneswar - 751019, ODISHA.

Contributions from DCOIWA to 74th IPC, Bengaluru

**Contributions from DCOIWA to 74th IPC, Bengaluru.-
Present : Mr. G Koteswar Rao, Dr. T. V. Narayana, Prof.
Milind Umekar and Prof. Raman Dang**

Click any where to read
all the DCOIWA Newsletters



E-Newsletter

DCOIWA News**Drugs Control Officers (I) Welfare Association (Regd)**



Blood Donation by Officers of Delhi Drug Control for Mr. Amit Kumar DI Jharkhand



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

- Organizing Secretary: Mr. Rakesh Dahiya
Vice-Presidents: Mr. Lalit Kumar Goel, Dr. M. Dhilip Kumar, Mr. D. R. Gahane, Mr. V. D. Dobaria, Dr. A. Ramkishan, Dr. Manish Kapoor, Mrs. Kanchan Sinha
Joint Secretaries: Mr. Rajkumar V. Zadbuke, Dr. S. Umesh, Mr. Pooran Chand, Mrs. Dipika Chauhan, Mr. Chandan Kumar Giri, Mr. Amit Kumar Bansal, Mr. Biswajit Talukdar
Treasurer: Dr. Parmanand Verma
EC Members: Dr. E. Ananda Kirouchenane, Mr. Venkatesh Sinari, Mrs. Garima Sharma, Mr. M. N. Sridhar, Mr. Ashutosh Kumar Chaube, Dr. Mahalakshmy .R, Dr. Zaffer Ahmad, Mr. Irap T. D. Toi, Mr. Ibom Ete, Mr. Neeraj Kumar, Dr. Mrinal Kanti Sarkar, Mr. Tapan Choudhry

Date: 11-10-2025
Place: Hyderabad

CONGRATULATORY MESSAGE

On behalf of the Drugs Control Officers India Welfare Association (DCOIWA), I extend my heartfelt appreciation and congratulations to the Delhi Drugs Control Officers and DCOIWA Delhi President Shri Deepak Sharma for their commendable humanitarian service.

Your timely and selfless act of donating blood for Shri Amith Kumar, Drugs Inspector, Jharkhand—who is currently undergoing treatment at Apollo Hospital, New Delhi—truly reflects the spirit of unity, compassion, and professional brotherhood within our fraternity.

As Apollo Hospital requires direct donors and does not accept outside blood, our officers have been coming forward one by one to meet the requirement. Till today, six officers have already donated blood, and many more stand ready to contribute whenever needed. This collective effort is deeply inspiring.

We sincerely pray for the speedy and complete recovery of Shri Amith Kumar. May he regain his health soon.

G. Koteswar Rao
National President, DCOIWA



H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.

FDA Haryana is Redefining Drug Safety and MSMEs Growth

The pharmaceutical sector is changing fundamentally in Northern India. Since taking office in August 2025, [Lalit Kumar Goel](#), the **State Drug Controller (SDC) of FDA Haryana**, has taken rapid changes to strengthen the drug regulatory framework as well as MSMEs growth.

From regulating the entry of counterfeit drugs to facilitating a streamlined **Schedule M compliance** for MSMEs, he aims to make Haryana the most attractive place for pharmaceutical operations while serving as a national beacon of pharmaceutical quality.

Digitization: A Seven-Day Timeline for MSMEs

One of the biggest deterrents to the pharmaceutical sector over the years was access to items that required prolonged "red tape" for approvals.

SDC **Lalit Kumar Goel** has proposed a **dual-mode digitized approval system** for business needs.

- **Expedited Approvals:** Additional approvals for drugs and cosmetics units are granted in **seven days**.
- **Hybrid Application:** Enterprises can apply for licenses/additional items through online and offline means to ensure all organizations are compliant.



MSMEs in Focus: Micro, Small, and Medium Enterprises can facilitate growth without bureaucratic burden.

Smart Time-Tracking: Toxic Solvent Usage

When spurious cough syrup deaths hit Punjab and other regions, Haryana was more than ready to implement its comprehensive **digital tracking application** via the ONDLS portal.

High-risk solvents include **Propylene Glycol (PG)** and **Glycerine**.

- **Data Uploads Required:** Each batch/vendor of solvent must be uploaded to track where they came from.
- **Legitimacy Tracking:** This ensures that everything has legitimate sources.

Ayush Recognition: Since Ayurveda

(Continued on page 26)

FDA Haryana is Redefining Drug Safety

(Continued from page 25)

cough syrups also use similar bases, the move applies to the Ayush sector as well to promote public safety.

Interstate Cooperation: Smuggling and Counterfeit Drugs

To combat psychotropic products and counterfeit substances, we need an inter-state approach.

Goel coordinated an **Inter-state Coordinating Committee** across seven states, including Punjab, Himachal Pradesh, J&K, and Uttarakhand.

On November 21, 2025, the FDA, CID and Police units met, and a final solution was determined: a centralized online portal listing NDPS information across all domains to share resources, conduct timely responses and implemented joint raids.

Compliance and Quality: Creating Revised Schedule M

As the state implements the **revised Schedule M (Good Manufacturing Practices)**, more than 118 allopathic manufacturers are coming under scrutiny.

Technological Implements at

Retailers: CCTV Cameras & Registration Requirements

Pharmacies cannot become hotspots for diversion/renting out necessary licenses to businesspersons attempting illegal sale without government intervention.

Therefore, the **FDA Haryana** has taken an external approach through technological implementations.

- **CCTV Requirement:** Any medical shop in Haryana must uphold a public-accessible CCTV system for sales activity.
- **Pharmaceutical Evidence Required:** Strict inspections must show that registered pharmacists are present; no "license-for-rent" systems can exist.

Sale and Purchase Records: During check visits, if the sale and purchase records do not align with audit trails, diversion is confirmed.

Source: [The Health Master](#)



Lalit Kt. Goel

10th edition of IP for standards of drugs in India

Drug quality standards in India are getting a boost as the [Indian Pharmacopoeia Commission \(IPC\)](#) will soon announce the newest release of the **10th edition of the Indian Pharmacopoeia 2026 (10th edition of IP 2026)**.

As the official standards for medicines manufactured and marketed across India, the release of a new edition is a **milestone for the pharmaceutical industry**.

Drug Standards, Pharmaceutical Industry Regulations, Official Drug Standards India, Indian Pharmacopoeia Monograph, Global Regulatory Standards

The New Gold Standard: The Indian Pharmacopoeia

The Indian Pharmacopoeia (IP) is the official standard book for **drugs and pharmaceutical preparations** in India.

Published by the IPC on behalf of the Ministry of Health and Family Welfare, Government of India, it supports the **Drugs and Cosmetics Act, 1940**, and its governing rules.

The IP essentially describes a drug or component's identity, purity, and strength; if a monograph, a specific entry within the IP does not exist for a drug or component, it is deemed illegal and essentially unsafe in India.

Therefore, it's a critical source for anyone in **pharmaceutical manufacturing** and drug testing.



Mandate: The IPC publishes each new Indian Pharmacopoeia edition periodically to include new drug monographs while revising others to meet current legal requirements reflecting other global regulatory standards.

Key Dates for the Release and Adoption of IP 2026

The initial release date and subsequent adoption of **IP 2026** will present a timeline to the industry for changes.

Four months after the official release indicates that **manufacturing**, testing laboratories, and **quality control** teams require several months to adopt all significant edits for full compliance.

What Changes?

The length of the 10th edition exceeds that of its predecessor significantly.

Thus, as India builds its pharmaceutical marketplace, it expands considerably in new additions and revisions to improve drug safety's scope and quality.

(Continued on page 28)

10th edition of IP for standards

(Continued from page 27)

New Additions at a Glance

Ultimately, the Indian Pharmacopoeia will encompass **3,340** total monographs in the new edition.

Total New Monographs: 121

- Drug Substances/Dosage Forms/Aids: 88
- Vitamins/Minerals/Amino Acids: 5
- Biotechnology-Derived Therapeutic Products: 2
- Human Vaccines: 3
- Blood & Blood Component Monographs: 20 (plus 2 additional blood-related products)
- Veterinary Vaccines: 1

Along with these new specifications for drugs, there are **five new general chapters**, including new testing strategies and requirements for drug safety and effectiveness.

Global Harmonization for Indian Pharmaceutical Exports

Perhaps most importantly, one of the IP 2026's highlights is **harmonization** with global pharmacopoeias.

With harmonized standards in place, Indian-made drugs will find fewer barriers to entry under similar standards already expected elsewhere in global markets.

Harmonized Standards in IP 2026:

- General Chapters Harmonized: 18
- Excipient Monographs Harmonized: 22

- Harmonized With: The members of the Pharmacopoeial Discussion Group (PDG): United States Pharmacopoeia (USP), European Pharmacopoeia (EP), Japanese Pharmacopoeia (JP)

This creates an additional international cachet for Indian drugs that previously may have been deemed untested or marked with unknown manufacturing methods.

Looking Back on the Previous IP (IP 2022)

The previous 9th edition revealed during IPC Conference 2022 in New Delhi brought forth continued enhancements.

- Total Monographs in IP 2022: 3,152
- New Monographs: 92
- New General Chapters: 12

Particularly prevalent were updated editions and revisions to align with global requirements and other major pharmacopoeias; updates included harmonization efforts with the British Pharmacopoeia (BP).

Source: [The Health Master](#)



FDA Haryana

Unlicensed Medical Store Operator Convicted Under Drugs & Cosmetics Act



The Hon'ble Court of Additional Sessions Judge, Faridabad has convicted Mausim, proprietor of M/s Riyaz Medicos, for illegally running an unlicensed medical store and selling allopathic medicines without a valid drug licence, in violation of the Drugs and Cosmetics Act, 1940.

The case pertains to an inspection conducted on 16 September 2019 by a team comprising of Karan Godara, the then SDCO Faridabad Sandeep Gahlain, The then DCO Faridabad-I and Pooja Chaudhary, the then DCO, Faridabad-II of FDA Faridabad zone at M/s Riyaz Medicos, located on Main Sohna Road, Village Sirohi, District Faridabad, based on secret information regarding illegal sale of medicines.

During the inspection, 81 varieties of allopathic drugs were found stocked for sale without any valid drug licence or registration.

The medicines were seized on the spot as per law.

During investigation, it was revealed that Mausim, the proprietor, had left the shop under the supervision of his associate Nasim, who admitted that the shop was being run without a valid licence.

The landlord of the premises also confirmed that the shop had been rented out to the accused.

After obtaining due sanction from the State Drugs Controller, Haryana, prosecution was launched.



The case was tried by the Sessions Court, where the prosecution examined five witnesses.

The Court held that the prosecution had proved the case beyond reasonable doubt.

Sentence Awarded

The Hon'ble Court sentenced the convict as follows:

Under Section 27(b)(ii) of the Drugs and Cosmetics Act, 1940:

Rigorous Imprisonment for 3 years and a fine of ₹1,00,000, with further imprisonment in default.

Under Section 28 of the Drugs and Cosmetics Act, 1940:

Rigorous Imprisonment for 6 months and a fine of ₹20,000, with further imprisonment in default.

This conviction underscores the strict action being taken by the Drugs Control Department against illegal sale of medicines and serves as a strong warning to those operating medical stores without proper authorization, posing serious risks to public health.

Source: Karan Singh, FDA Haryana

FDA Haryana

Fatehabad

16.12.25

Dheeraj Khatak DCO Fatehabad-II jointly raid with SI Ramchander PS Sadar Ratia.



Priya w/o Anil Kumar VPO Mahmadi Ratia is running a Kiryana store in her house. On searching the Kiryana store 140 (14x10) tablets of Tapentadol and 1500 (20x15x5) capsule of Pregabalin-300 were found stocked in this Kiryana store.

Tab Tapentadol or capsule Pregabalin stored illegally in her Kiryana store.

These recovered drugs were mainly misused by the youth as Medical intoxicant now a day.

All the recovered drugs sampled vide Form -17 & Form-17A action under D&C Act has been initiated by serving Show cause notice to accused person on the spot under 18A, 18(c) and 22(1)(CCA).

Source: Dheeraj Khatak, FDA Haryana

Hisar

09.12.2025

A team comprising Dr. Ajay Bishnoi, DCO Hisar-II, and Ajay Kumar, Hisar-I, under the supervision of the Senior Drugs Control Officer, Hisar Zone, conducted further investigation of the three firms M/s Iscon Distributor, Elder Formulation Pvt. Ltd., and Shree Mansa Mata Distributor situated at 64/4, Jain Gali, Hisar.



This action was in continuation of the raid conducted on 02.12.2025 at the residence of Prince Brain, Mandi Adampur, on secret information regarding illegal storage and sale of intoxicant medicines from his premises and his car (HR20AJ 0551).

Wherein 42,000 Tapentadol tablets (Tackdol-100 SR, Batch Nos. NPT-5783 and NPT-5782) were recovered, and Prince Brain disclosed that the intoxicant medicines were supplied by Narender Goel.

Further inspections were carried out on 08.12.2025 at the above-mentioned firms, and inspection reports of all three were prepared.

During the inspection of Shree Mansa Mata Distributor, the proprietor, Vatan, produced



Invoice No. NP2526T1319 dated 25.11.2025 issued by Nathan Pharma Pvt. Ltd., Baddi, for 2,329 boxes (6,98,700 tablets) of Tackdol-100 SR.

However, no stock was found, no sale records were produced, and the alleged sales-return invoice (CN00001 dated 30.11.2025), submitted to the team on 08.12.2025, appeared doubtful and bogus.

During a thorough search by the raid team, the original purchase bill of the said medicine was also found concealed in a hidden place, further

(Continued on page 31)

FDA Haryana

(Continued from page 30)

indicating deliberate suppression of records.

At Elder Formulation Pvt. Ltd., unauthorized packing materials and printed cartons namely one rim of Orrical D3 (Calcium carbonate, mg, Zinc, Vitamin D3, Batch DHN-017, Exp. 03/2027, mfg DOTTREL HEALTHCARE, Village Behra, Bhagwanpur Road, Derrabassi Industrial Area, SAS Nagar, Punjab – 140507, India.

One rim of Orrifol (ferrous Fumarate & Folic acid syrup) batch no. DHN-0018, exp. Date 3/27, mfg mfg DOTTREL HEALTHCARE, Village Behra, Bhagwanpur Road, Derrabassi Industrial Area, SAS Nagar, Punjab – 140507, India.

5 label on one sheet CE-Tin Plus Suspension (Paracetamol, phenylephrine & chlorphineramine Suspension (Batch 5060, Exp. 12/2026, mfg EDEN DRUGS PVT. LTD. (A GMP Certified Company) S.G.R.D.J. Airport Road, Meerankot, Distt. Amritsar (Punjab) – 143008).

60 label on one sheet of Gentader [gentamicin injection 20ml] (Batch 7772, Exp. 07/2026, mfg Instant Pharmaceuticals 48, Industrial Area, Rayon & Silk Mills, Near Old Octroi Post, Amritsar – 143104).

86 label of Dexader [Dexamethasone injection 20ml] batch no. 7771, exp. Dt 7/2026, mfg Instant Pharmaceuticals 48, Industrial Area, Rayon & Silk Mills, Near Old Octroi Post, Amritsar – 143104.

200 label of Orrizyme Syrup (Batch AP-3246, Exp. 07/2027), 200 label of Orrizyme Syrup (Batch AP-3247, Exp. 07/2027) mfg by AADVIK PHARMA, Plot No. 142, Barhi, HSIIDC, Ganaur, Haryana – 131101.

And all label under mfg in India under Elder Formulation Pvt. Ltd. Plot No. 791-92, Vipin Garden, Uttam Nagar, New Delhi – 110050 were recovered, indicating potential repacking



activities being carried out at the premises.

All certified packing materials, 6 Photos taken of premises on spot signed by team member and director Narender goyal of M/s Elder formulation pvt. Ltd, certified said label on one paper were collected, placed in one gatta box, properly sealed with the seal impression AKL, and signed by the raid team members along with Narender Goyal and Vatan Goyal (son of Narender Goyal and proprietor of Shree Mansa Mata Distributor).

All certified packing materials (Label) seized under vide Form 16.

It was established that all three firms M/s Iscon Distributor, Elder Formulation Pvt. Ltd., and Shree Mansa Mata Distributor are interconnected in their operations, belong to members of the same family, and are jointly involved in the illegal stocking, distribution, and attempted sale of Tackdol-100 SR (Tapentadol 100 mg), a medicine highly prone to misuse as an intoxicant.

The recovery of unauthorized packing material, the absence of lawful records, and the coordinated functioning of the three entities constitute grave violations of the Drugs and Cosmetics Act; therefore, to prevent furtherance of the offence, the entire premises of all three firms were sealed under Section 22(1)(d) of the Drugs and Cosmetics Act.

Source: Dr. Ajay Bishnoi, FDA Haryana

FDA Haryana

Hisar**08-12-2025**

With reference to the raid conducted on 02.12.2025 at the residence of Prince Brain, Mandi Adampur, based on secret information regarding illegal storage and sale of intoxicant medicines from him.



In continuation of the investigation, on 08.12.2025, a visit was conducted by Sh. Ajay Kumar, Hisar-I and Sh. Ajay Bishnoi DCO Hisar-II to M/s Iscon, Elder Formation, and Shree Mansa Mata Distributor, situated at 64/4, Jain Gali, Hisar. Inspection reports of all three firms were prepared.

During the inspection of Shree Mansa Mata, the proprietor Mr. Vatan was found present. He produced INVOICE No. NP252611319 dated 25.11.2025, issued by

Nathan Pharma Pvt. Ltd., Plot No. 8, DIC Industrial Area, Baddi, Solan (H.P.)–173205, showing purchase of 2,329 boxes, each containing 300 tablets, totalling 6,98,700 Tapentadol tablets. However, no corresponding stock was found on the premises, and only the purchase invoice was available.

The proprietor, Mr. Vatan, submitted a written statement and produced a sales-return invoice No. CN00001 dated 30.11.2025, purportedly issued to Nathan Pharma Pvt. Ltd. So to verify that firm actually Return the stock or distribute in market, as the firm was found to be involved in purchase of large quantity of medical intoxicant, Accordingly, to prevent furtherance of the offence, the premises of the firm M/s Shree Mansa Mata Distributor were sealed under Section 22(1)(d) of the Drugs and Cosmetics Act.

Source: Dr. Ajay Bishnoi, FDA Haryana

Karnal**08.12.2025**

A team of Drugs Control Officer Karnal-1 along with officials of HSNCB Karnal headed by ASI Balinder Singh raided at M/s Guru Nanak Medical Store situated at Opposite Central Jail, Kaithal Road, Karnal in order to investigate a complaint regarding illegal sale of dual use prescription drugs.



After scrutinizing records, it was found that the firm purchased approximate 1500 vials of Pheniramine Maleat Injection 100ml for veterinary use since April 2025 and sold them without maintaining sale records.

The firm was indulge in illegal sale of dual use prescription drugs without any prescription of RMP.

The veterinary 100ml vials of Pheniramine Maleat Injection were being sold the firm illegally as intoxicants.

Moreover without any record, 20 tablets of Buperinorphine tablets were also recovered from the premises.

Moreover two drugs samples were taken from the firm for testing. So to Stop the furtherance of the offence, the premise was sealed.

Source: Vikas Rath, FDA Haryana

FDA Haryana

Hisar

02.12.2025


A joint team of CM Flying and Dr. Ajay Kumar Bishnoi, DCO Hisar-II, raided the residence of Prince Brain at Mandi Adampur on secret information regarding illegal storage and sale of intoxicant medicines from his premises and his Car (HR20AJ 0551).

The vehicle, registered in the name of Bupender Kumar, was confirmed by him (through phone and handwritten statement) to be sold to and in possession of Mr. Prince Brain.

The car was opened using keys produced by him (photo taken and signed team members).



A total of 42,000 Tapentadol tablets (Tackdol 100 SR and ZATTDOL-100 SR) and 3,400 Pregabalin capsules (Neuro-300) were recovered.



Prince Brain failed to produce any drug licence or purchase/sale records.

Samples of all three drugs were drawn and remaining stock was seized under Form-16, packed in two gatta boxes, sealed with AKB, and his statements were recorded.

Source: Sarika Malik, SDCO, FDA Haryana



FDA Haryana

Sirsa**01.12.2025**

Suneel Kumar, Drugs Control Officer, Sirsa-II alongwith police official of PP Singhpura raided on M/s Khushi medical Store ,Village Dharpura a secret complaint of above said firm regarding illegal stocking & selling of medical intoxicated drug's.During thoroughly Checking,600 Tablets of Tapentadol Tablets & 1200 Capsules of Pregabalin Capsules IP 300 mg recovered from the premises and the Mr.Khuswinder Singh (Prop.) of the firm Could not produce any sale/purchase records of these medical intoxicated drug's .These drug's sampled vide on Form-17.Inspection report Filled & shop

sealed .Further action will be taken as per D&C Act.

In the evening on 02.12.2025 joint raid was conducted with CIA police by Suneel Kumar DCO Sirsa-II &19500 Tab Tackdol 100 SR (Tapentadol Hydrochloride) total were seized vide Form 16 from the possession of Amandeep Singh and Vikas when they were carrying out drugs for illegal supply near Dabwali. These person were worker /sales person of the firm which was sealed during joint raid dated 03.11.25 at VPO Odhan (KALANWALI) Further action has been initiated as per D& C Act by the DCO Sirsa.

Source: Suneel Kumar, DCO, FDA Haryana



FDA Haryana in news



FDA Haryana in news

Haryana State Pharmacy Council meeting: Sh. Rakesh Dahiya Asstt. State Drugs Controller, FDA Haryana representing Stata Drugs Controller FDA Haryana as Ex Officio Member



FDA Haryana in news

बिना लाइसेंस मेडीकल स्टोर चलाने पर तीन साल की सजा, एक लाख जुर्माना एफडीए की सख्त कार्रवाई के परिणाम आने लगे सामने

फरीदाबाद, 23 दिसम्बर, सत्यजय टाइम्स/रूपेश बंसल। कोर्ट ने दिए एक महत्वपूर्ण फैसले में बिना लाइसेंस मेडीकल स्टोर संचालक को दोषी करार दिया है। माननीय अतिरिक्त सत्र न्यायाधीश, फरीदाबाद की अदालत ने रियाज मेडिकोज, के प्रोप्राइटर मौसिम को बिना वैध ड्रग लाइसेंस के मेडिकल स्टोर संचालित करने तथा एलोपैथिक दवाइयों की अवैध बिक्री करने के अपराध में ड्रग्स एवं कॉस्मेटिक्स अधिनियम, 1940 के अंतर्गत दोषी ठहराया है।



तत्कालीन डीसीओ फरीदाबाद-दो पूजा, शामिल थी। निरीक्षण के दौरान बिना किसी वैध ड्रग लाइसेंस अथवा पंजीकरण के बिक्री हेतु रखी गई एलोपैथिक दवाइयों की 81 किस्में पाई गईं, जिन्हें कानून के अनुसार मौके पर ही जब्त कर लिया गया।

जांच के दौरान यह सामने आया कि प्रोप्राइटर मौसिम दुकान छोड़कर चला गया था और दुकान उसके सहयोगी नसीम को देखरेख में चल रही थी। नसीम ने स्वीकार किया कि

सुनवाई के बाद माननीय न्यायालय द्वारा दोषी को ड्रग्स एवं कॉस्मेटिक्स अधिनियम, 1940 की धारा 27(ब)(दो) के अंतर्गत 3 वर्ष का सश्रम कारावास एवं 1,00,000 रुपए का जुर्माना, जुर्माना अदा न करने पर अतिरिक्त कारावास की सजा सुनाई गई। साथ ही ड्रग्स एवं कॉस्मेटिक्स अधिनियम, 1940 की धारा 28 के अंतर्गत 6 माह का सश्रम कारावास एवं 20,000 रुपए का जुर्माना, जुर्माना अदा न करने पर अतिरिक्त कारावास की सजा भी सुनाई गई। यह कार्रवाई औषधि नियंत्रण विभाग द्वारा दवाओं की अवैध बिक्री के विरुद्ध की जा रही सख्त कार्रवाई का जीता जागता प्रमाण है। जो कि बिना उचित प्राधिकरण के मेडिकल स्टोर संचालित करने वालों के लिए एक कड़ा संदेश देने का काम करेगा। क्योंकि ऐसी गतिविधियां जन-स्वास्थ्य के लिए गंभीर खतरा उत्पन्न करती हैं।

बिना लाइसेंस मेडिकल स्टोर चलाने पर सख्त सजा, फरीदाबाद कोर्ट ने संचालक को 3 साल की कैद सुनाई

अक्षय कुमार शर्मा

फरीदाबाद : ड्रग्स एंड कॉस्मेटिक्स एक्ट, 1940 का उल्लंघन कर बिना वैध लाइसेंस के एलोपैथिक दवाइयों की बिक्री करने के मामले में फरीदाबाद की माननीय अतिरिक्त सत्र न्यायालय ने मौसिम रियाज मेडिकोज के संचालक मौसिम को दोषी ठहराते हुए कड़ी सजा सुनाई है। अदालत ने आरोपी को 3 वर्ष के कठोर कारावास और 1 लाख के जुर्माने से दंडित किया है।

यह मामला 16 सितंबर 2019 का है, जब फूड एंड ड्रग्स एडमिनिस्ट्रेशन, फरीदाबाद की टीम ने गुप्त सूचना के आधार पर मेन सोहना रोड, गांव सिरौही स्थित एक मेडिकल स्टोर पर छापेमारी की थी। जांच के दौरान दुकान में 81 प्रकार की एलोपैथिक दवाइयों बिना किसी वैध ड्रग लाइसेंस या पंजीकरण के बिक्री हेतु रखी हुई पाई गईं, जिन्हें मौके पर ही कानून के तहत जब्त कर लिया गया। छापेमारी दल में तत्कालीन वरिष्ठ ड्रग नियंत्रक अधिकारी श्री करण गोदारा, डीसीओ फरीदाबाद-क श्री संदीप गहलैन तथा डीसीओ फरीदाबाद-क श्रीमती पूजा शामिल थीं। जांच में यह तथ्य सामने आया कि दुकान का संचालन आरोपी मौसिम द्वारा किया जा रहा था, जबकि उसके अनुपस्थित रहने पर दुकान उसके सहयोगी नसीम के हवाले कर दी गई थी। नसीम ने जांच



अधिकारियों के समक्ष स्वीकार किया कि दुकान बिना किसी वैध लाइसेंस के चलाई जा रही थी। वहीं, दुकान के मकान मालिक ने भी पुष्टि की कि परिसर आरोपी को किराए पर दिया गया था। राज्य औषधि नियंत्रक, हरियाणा से विधिवत अनुमति प्राप्त करने के बाद अभियोजन शुरू किया गया। मामले की सुनवाई के दौरान अभियोजन पक्ष ने पांच गवाहों को अदालत में पेश किया। न्यायालय ने सभी साक्ष्यों

का अवलोकन करते हुए माना कि अभियोजन पक्ष ने आरोपी को सख्त सजा सुनाई गई सजा धारा 27 के तहत: 3 वर्ष का कठोर कारावास एवं 1,00,000 का जुर्माना धारा 28 के तहत: 6 माह का कठोर कारावास एवं 20,000 का जुर्माना (जुर्माना अदा न करने पर अतिरिक्त सजा का प्रावधान) यह फैसला बिना लाइसेंस के मेडिकल स्टोरों के खिलाफ ड्रग्स

कंट्रोल विभाग की सख्त कार्रवाई को दर्शाता है। साथ ही यह उन सभी लोगों के लिए कड़ा संदेश है जो नियमों को ताक पर रखकर दवाइयों की अवैध बिक्री कर जनस्वास्थ्य से खिलवाड़ कर रहे हैं। वहीं इस मामले में औषधि नियंत्रक ललित भोवला का कहना है कि बिना वैध लाइसेंस दवाइयों की बिक्री जनस्वास्थ्य से सीधा खिलवाड़ है। ऐसे मामलों में ड्रग्स कंट्रोल विभाग किसी प्रकार की हिदायत नहीं बतता।

शीला बाईपास दवा विक्रेता के पास मिला नशीली दवाओं का जखीरा, संचालक गिरफ्तार, दुकान सील

जागरण संवाददाता • रोहतक: जिला औषधि नियंत्रण अधिकारी और एंटी नारकोटिक्स सेल रोहतक की संयुक्त टीम ने नशे के खिलाफ बड़ी कार्रवाई करते हुए शनिवार देर रात साढ़े 10 बजे शीला बाईपास स्थित पूनम मेडिकल हाल पर छापेमारी की। यह कार्रवाई गुप्त सूचना के आधार पर की गई, जो एक दिन पूर्व पकड़े गए नशा तस्करों से मिले इनपुट के बाद अंजाम दी गई। छापेमारी के दौरान मेडिकल स्टोर से भारी मात्रा में प्रतिबंधित नशीली दवाएं बरामद की गई हैं। जिला औषधि नियंत्रण अधिकारी मनदीप मान ने बताया कि टीम ने मेडिकल हाल के संचालक राजीव गुप्ता की कैमिस्ट दुकान से कुल 2970 गोलियां प्रिगैबलिन, 510 गोलियां टेपेंटोडोल और अन्य नारकोटिक्स श्रेणी की दवाएं बरामद कीं। इसके अलावा तीन अन्य प्रकार की प्रतिबंधित दवाएं भी मिलीं,



जिला औषधि नियंत्रण अधिकारी मनदीप मान जांच करते हुए। • जागरण

जिनकी संख्या लगभग 460 गोलियां व इंजेक्शन बताई गई है। जांच में सामने आया कि ये सभी दवाएं दुकान के वैध लाइसेंस में शामिल नहीं थीं और इस प्रकार की दवाओं का रखना व बिक्री करना कानूनन अपराध है। अधिकारियों ने बताया कि मेडिकल स्टोर को जो लाइसेंस विभाग की ओर से जारी किया गया था, उसके अंतर्गत इन दवाओं का भंडारण और बिक्री पूरी तरह से

प्रतिबंधित है। प्राथमिक जांच में यह भी सामने आया है कि यह दवाएं नशेदियों को बेची जा रही थीं, जिससे युवाओं में नशे की लत बढ़ रही थी।

दवा विक्रेता के खिलाफ एफआईआर दर्ज : कार्रवाई के दौरान दवा विक्रेता के खिलाफ एनडीपीएस एक्ट के तहत एफआईआर दर्ज कर उसे मौके पर ही गिरफ्तार कर लिया गया। साथ ही ड्रग्स एंड कॉस्मेटिक्स एक्ट के अंतर्गत भी कार्रवाई की गई है। विभागीय नियमों के अनुसार मेडिकल स्टोर का लाइसेंस रह करने की प्रक्रिया शुरू कर दी गई है और फिलहाल दुकान को सील कर दिया गया है। जिला औषधि नियंत्रण अधिकारी मनदीप मान ने बताया कि आरोपी राजीव गुप्ता को रविवार को अदालत में मजिस्ट्रेट के समक्ष पेश किया जाएगा और रिमांड की मांग की जाएगी।

मेडिकल मोड़ से दो नशा तस्कर गिरफ्तार, 342 गोलियां बरामद

रोहतक | ड्रग विभाग की टीम ने मेडिकल मोड़ पर दो नशा तस्करों को दबोचा है। उनके पास से नशे की गोलियां बरामद की गई है। दोनों के खिलाफ केस दर्ज किया है। टीम को अपने नेटवर्क के जरिए मेडिकल मोड़ पर नशे की गोलियां बेचने की जानकारी मिली। इस पर टीम मौके पर पहुंची। यहां पर दो नशेदियों को नशे की गोलियां बेचने की कोशिश करते हुए दिखाई दिया। शक के आधार पर दोनों को दबोच लिया। उनके पास से टपेंटाडोल नामक 342 गोलियां बरामद हुईं। जिनको नशे के लिए इस्तेमाल करते हैं और इस प्रकार इनकी बिक्री करना प्रतिबंधित है। साथ ही दोनों आरोपी गोलीयों की खरीद का बिल या दवा बेचने का परमिट नहीं दिखा पाए। पूछताछ में आरोपियों ने खुद को तहसील महम के गांव फरमाणा खास निवासी कुलबीर सिंह और राजस्थान राज्य में सीकर गांव निवासी अभिषेक बताया। जिला औषधि नियंत्रण अधिकारी मनदीप मान ने बताया कि दोनों आरोपियों के खिलाफ ड्रग्स एवं कॉस्मेटिक एक्ट के तहत कार्रवाई की गई है।



हिंदी आंदोलन के सत्याग्रही

FDA Haryana in news

कार्रवाई • विवाद या अप्रिय स्थिति से निपटने के लिए पुलिस भी रही अभियान में शामिल ड्रग विभाग फरीदाबाद की टीम ने रतिया में की मेडिकल स्टोर्स की चेकिंग, हड़कंप

भारत न्यूज़ | रतिया

मेडिकल संचालकों को पुलिस की चेतावनी- रिकॉर्ड न मिला तो होगी कार्रवाई

ड्रग्स विभाग हरियाणा की टीम ने बुधवार को रतिया में मेडिकल स्टोर्स पर नशीली दवाओं और मेडिकल नशों पर रोक लगाने के लिए ब्यापक चेकिंग अभियान चलाया। इस अभियान का नेतृत्व फरीदाबाद के ड्रग्स निरीक्षक संदीप कुमार ने किया। विवाद या किसी अप्रिय स्थिति से निपटने के लिए पुलिस टीम भी अभियान में शामिल रही।

टीम ने संजय गांधी चौक, फतेहबाद रोड, टोखना रोड, खटीक मोहल्ला और सरदुलगाड़ कैचियों सहित शहर के आधा दर्जन मेडिकल स्टोर्स की जांच की। चेकिंग के दौरान विभाग ने पहले से तैयार मेडिकल स्टोर्स की सूची का उपयोग किया। अभियान का उद्देश्य रतिया में बढ़ते मेडिकल नशों पर अंकुश लगाना था। हालांकि, इस दौरान टीम को कोई बड़ा उल्लंघन हाथ नहीं लगा।

युवाओं को नशे की गिरफ्त से बचाने के लिए पुलिस ने मेडिकल संचालकों को कड़ी चेतावनी दी। एसपी सिद्धांत चैन ने कक्षा कि कार्रवाई का उद्देश्य नशीली दवाओं की अवैध बिक्री रोकना और युवाओं को नशे की गिरफ्त से बचना है। जांच में देखा जा रहा है कि कहीं किसी भी प्रकार की नशीली दवायों, सिरिज या प्रतिबंधित दवाएं बिना डॉक्टर की वृध पत्रों के तो नहीं बेची जा रही। मेडिकल संचालकों को सख्त निर्देश दिए गए कि वे बिना डॉक्टर की पत्रों के किसी भी नशीली दवा, इंजेक्शन या सिरिज किसी को भी न दें। उल्लंघन पाए जाने पर संबंधित मेडिकल संचालक के खिलाफ कड़ी कानूनी कार्रवाई की जाएगी। साथ ही, मेडिकल स्टोर्स संचालकों से कक्षा गया कि वे किसी नए पुरा रिकॉर्ड रखें और समय-समय पर संबंधित विभाग को सहयोग दें।



रतिया। मेडिकल स्टोर पर चेकिंग करते डीआई।

नशे से हुई युवक की मौत के बाद एवशन तेज स्टेट ड्रग विभाग ने रतिया में 5 मेडिकल दुकानों पर दी दबिश

■ किसी रिकॉर्ड और प्रतिबंधित नशीली दवाओं को उपलब्ध की गहनता से जांच की

हरिद्वीप न्यूज़ | रतिया



रतिया। मेडिकल दुकानों पर जांच करते अधिकारी।



फोटो: हरिद्वीप

जायी रहेगा अभियान

टीम के जय केशव शहर वारा प्रमोी पुरा विभाग ने कहा कि यह अभियान नशियों से भी जारी रहेगा। शहर में किसी भी नूतन में प्रतिबंधित दवाओं की बिक्री बंद होनी चाहिए। टीम के अनुसार, ड्रग्स विभाग स्टोर्स के रिकॉर्ड में बिक्री पाई जायेगी। उसके विभाग ड्रग्स पद कंट्रोलिंग पद के तहत सख्त कार्रवाई करवाई की जायेगी। बता दें कि रतिया में पिछले दिनों बरे को अंतराक्षेत्र से एक युवक की मौत हो गई थी। इसके बाद एवचने से रतिया एवशन की टीम लखनऊ कर शिव ध पत्नी मेडिकल स्टोर संचालक को इन मामलों में विचारण कर दिया था। इनके बाद से ही पुलिस मेडिकल स्टोर संचालकों की जांच कर रही है।

इन मेडिकल स्टोर्स पर की जांच

एवशन को पुरा विभाग ने बताया कि अभियान के दौरान विवाद मेडिकल, नुरी मेडिकल, जालपुर मेडिकल, अरुण मेडिकल, सारोष जालपुर मेडिकल एवं बाबा जे मेडिकल हीन सहित अन्य मेडिकल स्टोर्स की गहनता से जांच की गई। दवाओं के स्टॉक रजिस्टर, बिक्री रिकॉर्ड तथा लाइसेंस संबंधी दस्तावेजों को भी उपलब्ध की गई, ताकि किसी भी प्रकार की अवैधता को समय रहते रोका जा सके। विभाग के दौरान सभी मेडिकल संचालकों को सख्त शब्दों में चेतावनी दी गई कि वे बिना डॉक्टर की पत्रों के किसी भी प्रकार की नशीली दवा, इंजेक्शन या सिरिज किसी को भी न दें। बिक्री का उपलब्ध पाए जाने पर संबंधित मेडिकल संचालक के विरुद्ध कड़ी कानूनी कार्रवाई की जायेगी। इस ही उद्देश्य से ही निरीक्षण किए गए कि वे किसी का पुरा रिकॉर्ड रखें और समय-समय पर संबंधित विभाग को सहयोग प्रदान करें।

कृष्ण कुमार ने बताया की स्टेट ड्रग विभाग और स्टेट नारकोटिक्स की टीमों ने मिलकर इस अभियान को अंजाम दिया है इस दौरान टीम ने मेडिकल स्टोर्स में प्रतिबंधित दवाइयां सहित वहा रखे गए रजिस्टर और डॉक्टर के पर्चे का मिलान किया गया ताकि विना

अनुमति नशीली दवाओं को किसी को भी बिक्री पर रोक लगाई जा सके। हालांकि, आपतजनक दवा नहीं लगी है, युधवार दोपहर तक चली इस शुरुआती कार्रवाई में टीम के हाथ शाम तक जारी रही।



The accused with the seized drugs.

Drugs worth ₹10 lakh seized in raid at jeweller's house at Sirsa village

SIRSA, DECEMBER 16

The police in Sirsa district raided the house of a jeweller at Nagoki village and seized a large quantity of drugs used for intoxication, officials said on Monday. The seized medicines are valued at around Rs 10 lakh. Sirsa Superintendent of Police Deepak Saharan said the Anti-Narcotic Cell received information that a man identified as Mohan Lal, who runs a jewellery business, was allegedly selling intoxicating medicines under the cover of his trade.

Following the tip-off, the police team, along with Drug Control Department officials Sunil Kumar and Keshav Vashisht, conducted a raid at Mohan Lal's house. During

the search, police recovered 22,760 Tapentadol tablets and 21,600 Pregabalin capsules, both commonly misused as drugs. The seized tablets and capsules, along with the accused, were handed over to the Drug Control Department for further action. Drug Control Officer Keshav Vashisht said a notice has been issued to Mohan Lal and further legal proceedings will follow.

Sources said, Mohan Lal's son and a relative run a medical store elsewhere. The drugs were allegedly stored at the house instead of the medical shop to avoid police action and to enable supply both through the shop and within the village.— OC

जैन गली में एफडीए की कार्रवाई, अवैध पैकिंग, रिम और लेबल सामग्री मिली 2329 बाँक्सों में 6 लाख 98 हजार नशीली दवा मिलीं, न रिकॉर्ड, न बिल, 3 फर्म सील

भारत न्यूज़ | हिसार

एफडीए की टीम ने मंगलवार को जैन गली में तीनों फर्मो की जांच के दौरान नशीली दवा टेकाडोल 100 एसआर के 2329 बाँक्स से 6 लाख 98 हजार 700 टेबलेट बरामद की। फर्मों से अवैध पैकिंग, रिम और लेबल सामग्री मिली। टीम ने ड्रग एंड कॉस्मेटिक एक्ट के तहत नॉट्रेंड गोयल और उसके बेटे की तीनों फर्मो को सील कर दिया।

2 दिसंबर को एफडीए टीम ने आदमपुर में प्रिंस के घर पर छपा मारा था। कार से 42,000 टैपेंटाडोल गोयलियां मिली। टीम की जांच में सप्लायर के रूप में हिसार के नॉट्रेंड गोयल का नाम सामने आया था। एफडीए ने की जांच की तो सामने आया कि नॉट्रेंड गोयल एवं उसके बेटे की जैन गली में दवा की



कार्रवाई के दौरान एफडीए टीम।

नॉलेज पार्ट

■ दवा लाइसेंस होल्डर कोई दवा विक्रेता प्रतिबंधित दवाएं डॉक्टर के पर्चे पर बेच सकता है। रिकॉर्ड रखना होता है।
■ दवा विक्रेता को स्टॉक भी मॉनिटर रखना होता है। कितनी आई और कितने बेची और किस बेची, कितनी शेष है। यदि रिकॉर्ड मॉनिटर नहीं है तो कार्रवाई हो सकती है।

तीन फर्म हैं। एफडीए की टीम गठित हुई। इसमें डीसीओ हिसार डॉ. अजय बिश्नोई एवं अजय कुमार, वरिष्ठ दवा नियंत्रण अधिकारी सारिका मलिक को शामिल किया। टीम ने मंगलवार को जैन गली स्थित तीन फर्मो एएसएस इस्कॉन डिस्ट्रीब्यूटर, एल्डर फोर्मुलेशन प्राइवेट लि. और श्री मनसा माता डिस्ट्रीब्यूटर पर पहुंची। इस दौरान श्री मनसा माता डिस्ट्रीब्यूटर द्वारा नाथन फार्मा प्राइवेट लिमिटेड से तैयार कराई गई टेकाडोल 100 एसआर टेबलेट के 2,329 बाँक्स बरामद हुए। इनमें 6,98,700 टेबलेट मिली। वहीं फर्म संचालक ने न तो दवाओं का किल दिखाया और न स्टॉक बताया। इन टेबलेट्स का क्वी बैच था जो आदमपुर में प्रिंस को सप्लाई किया गया था।

FDA Haryana in news

रात दस बजे भी सक्रिय दिखाई दिए औषधि नियंत्रक अधिकारी संदीप गहलान दुकान बंद करते समय कर रहे हैं फ्रिजों की जांच

फरीदाबाद, 06 दिसम्बर, सत्यजय टाईम्स/सुनील अग्रवाल। केमिस्ट दुकानों में दवाओं के सुरक्षित भंडारण हेतु रेफ्रिजरेटर की कार्यशीलता और रात को चलने की सघन जांच पूरे हरियाणा में की जा रही है, विशेषकर दुकानों के सुबह खुलने के समय तथा रात्रि में बंद होने के समय।

इसी क्रम में संदीप गहलान, औषधि नियंत्रण अधिकारी, फरीदाबाद (जिनके पास जिला पलवल का अतिरिक्त कार्यभार भी है) द्वारा 5 दिसम्बर को प्रातः 7:30 बजे से 10 बजे तक जिला पलवल के पृथला गांव में 3, भगोला में 5 तथा कुसलीपुर में 4 मेडिकल स्टोर्स का निरीक्षण किया गया।

निरीक्षण के दौरान रेफ्रिजरेटर में बनी ठंडक एवं जमी हुई बर्फ के आधार पर यह परखा गया कि रात के समय भी रेफ्रिजरेटर चालू रखा गया था या नहीं। सभी दुकानों के रेफ्रिजरेटर चालू हालत में मिले।

इसी निरंतरता में रात्रि 9 बजे से 11 बजे तक



फरीदाबाद में ओल्ड फरीदाबाद चौक पर 2, फ्रेंड्स कॉलोनी में 2, गांधी कॉलोनी में 1, फतेहपुर चदीला में 1, और सेक्टर 21-डी में 5 मेडिकल स्टोर्स का निरीक्षण किया गया जिस दौरान सभी दुकानों के

रेफ्रिजरेटर चालू मिले। साथ ही दुकानों में लगे सीसीटीवी कैमरों की कार्यशीलता एवं रिकॉर्डिंग की भी जांच की गई। जिन दुकानों में सीसीटीवी रिकॉर्डिंग 30 दिनों से कम पाई गई, उन्हें 2 दिनों के भीतर स्टोरेज क्षमता बढ़ाने के निर्देश दिए गए। श्री गहलान ने बताया कि कोल्ड स्टोरेज दवाओं के लिए 2 से 8 डिग्री सेल्सियस तापमान अनिवार्य है, इसी कारण समय-समय पर सभी केमिस्टों को 24/7 रेफ्रिजरेटर चालू रखने के निर्देश दिए गए हैं।

साथ ही, जिला उपायुक्त के निर्देशों के अनुसार सभी दुकानों में सीसीटीवी कैमरे लगाना आवश्यक है, जिनमें कम-से-कम 30 दिनों की रिकॉर्डिंग सुविधा होनी चाहिए। आगामी दिनों में भी इस प्रकार की जांच एवं छापेमारी जारी रहेगी। यदि किसी दुकान का रेफ्रिजरेटर बंद पाया गया, तो मौके पर दवाइयों को जब्त कर कानूनी कार्रवाई की जाएगी तथा आवश्यकतानुसार दुकान को सील भी किया जाएगा।

सार्थक मुहिम डिस्पोजल फ्री डिस्पोजल फ्री विवाह अपनाने वाले जिलाध्यक्ष सचिन ठाकुर ने कहा भी मजबूत करेगी। दौरान सोसायटी के सदस्यों एवं स्थानीय निवासियों की उपस्थिति रही।

माजिक आर ना और कर रीब बाबा गते पुष्प दिवस हे नकर रहे हैं

दृष्टि गी रियाणा 31. गी. हबन

देर रात फरीदाबाद व पृथला विधानसभा में चला औषधि नियंत्रण अधिकारी डंडा

रेफ्रिजरेटर पाया बंद तो दवाई जब्त कर करेंगे कार्रवाई : संदीप गहलान

■ उपायुक्त के निर्देशों के अनुसार सभी दुकानों में सीसीटीवी कैमरे लगाना आवश्यक है जिनमें कम-से-कम 30 दिनों की रिकॉर्डिंग सुविधा होनी चाहिए

डॉ संदीप पराशर

फरीदाबाद(पृथला)। राज् औषधि नियंत्रक, एफडीए हरियाणा ललित गोयल के निर्देशानुसार केमिस्ट दुकानों में दवाओं के सुरक्षित भंडारण हेतु रेफ्रिजरेटर की कार्यशीलता और इसके देर रात को चलने की सघन जांच पूरे हरियाणा में की जा रही है। विशेषकर दुकानों के सुबह खुलने के

समय तथा रात्रि में बंद होने के समय इसी क्रम में औषधि नियंत्रण अधिकारी, फरीदाबाद संदीप गहलान पृथला विधानसभा के गांव में 3, बघोला में 5 तथा कुसलीपुर में 4 मेडिकल स्टोर्स का औचक निरीक्षण किया गया। निरीक्षण के दौरान रेफ्रिजरेटर में बनी ठंडक एवं जमी हुई बर्फ के आधार पर यह परखा गया, रात के समय भी रेफ्रिजरेटर चालू रखा गया था या नहीं। सभी दुकानों के रेफ्रिजरेटर चालू हालत में मिले। इसी निरंतरता में लगभग रात्रि 9 बजे से 11 बजे तक फरीदाबाद में ओल्ड फरीदाबाद चौक पर 2, फ्रेंड्स कॉलोनी में 2, गांधी कॉलोनी में 1, फतेहपुर चदीला में 1, और सेक्टर 21-डी में 5 मेडिकल स्टोर्स का निरीक्षण किया गया जिस दौरान सभी दुकानों के रेफ्रिजरेटर चालू मिले। साथ ही दुकानों में लगे सीसीटीवी कैमरों की कार्यशीलता एवं रिकॉर्डिंग की भी जांच

की गई। जिन दुकानों में सीसीटीवी रिकॉर्डिंग 30 दिनों से कम पाई गई, उन्हें 2 दिनों के भीतर स्टोरेज क्षमता बढ़ाने के निर्देश दिए गए। गहलान ने बताया कि कोल्ड स्टोरेज दवाओं के लिए 2 से 8 डिग्री सेल्सियस तापमान अनिवार्य है, इसी कारण समय-समय पर सभी केमिस्टों को 24-7 रेफ्रिजरेटर चालू रखने के निर्देश दिए गए हैं।

साथ ही, जिला उपायुक्त के निर्देशों के अनुसार सभी दुकानों में सीसीटीवी कैमरे लगाना आवश्यक है जिनमें कम-से-कम 30 दिनों की रिकॉर्डिंग सुविधा होनी चाहिए। आगामी दिनों में भी इस प्रकार की जांच एवं छापेमारी जारी रहेगी। यदि किसी दुकान का रेफ्रिजरेटर बंद पाया गया, तो मौके पर दवाइयों को जब्त कर कानूनी कार्रवाई की जाएगी तथा आवश्यकतानुसार दुकान को सील भी किया जाएगा।



मेडिकल स्टोर की जांच करते हुए औषधि नियंत्रण अधिकारी, फरीदाबाद संदीप गहलान अपनी टीम के साथ।

Send your news and articles to:
dcoiwanewsletter@gmail.com





23

Telangana



GOVERNMENT OF TELANGANA
DRUGS CONTROL ADMINISTRATION



Press Note

Press Note No. 89/DCA/2025

Date: 11-12-2025

Drugs Control Administration, Telangana, conducted a raid on an unlicensed premises at **Mythri Sri Fertility Centre, Hanamkonda**, and seized drugs worth **Rs. 5.82 lakhs** that were illegally stocked for sale in contravention of the provisions of the Drugs and Cosmetics Act.

The details are as follows:

On 10th December 2025, officials of the Drugs Control Administration, Telangana, acting on credible information regarding the illegal stocking and sale of medicines, conducted a raid on an unlicensed premises located at **Mythri Sri Fertility Centre**, beside the Head Post Office, Ambedkar Circle, Hanamkonda.

During the raid, the DCA officers detected the stocking of a large quantity of medicines intended for sale in contravention of the provisions of the Drugs Rules made under the Drugs and Cosmetics Act, 1940. A total of **35 varieties** of medicines were found at the premises, including steroids and hormone preparations used to treat infertility. The officers seized the stock, worth **Rs. 5.82 lakhs**.

Dr. G. Rajyalakshmi, Assistant Director, Warangal; Sri J. Kiran Kumar, Drugs Inspector, Hanumakonda; and Sri A. Balakrishna, Drugs Inspector, Jangaon, were among the officers who carried out the raid.



Telangana

DCA officers lifted the samples for analysis. Further investigation shall be carried out and action shall be taken as per the law against all the offenders.

The Drugs Control Administration, Telangana, advises all **qualified practioners/registered medical practitioners** that while Schedule K of the Drugs Rules exempts them from obtaining a drug licence for supplying medicines to their own patients — provided the registered medical practitioner is not operating an open shop or selling over the counter — **strict compliance with the following Rules is mandatorily required.**

- Medicines must be purchased only from licensed dealers or manufacturers, and purchase bills must clearly mention the drug names, quantities, and batch numbers.
- A proper register must be maintained, recording the name of the medicine, quantity issued, prescribed dose, patient details, date of supply, and the doctor’s name at the time of issue.
- These registers must be preserved for a minimum period of two years.

The public is urged to be aware of these legal requirements to ensure safe and regulated access to medicines.

The public may report any complaints regarding illegal activities related to medicines, as well as any other suspected manufacturing activities concerning drugs, including narcotic drugs and psychotropic substances, in residential, commercial, or industrial areas through the **Drugs Control**

Telangana

Administration, Telangana Toll-Free Number 1800-599-6969, operational from 10:30 am to 5:00 pm on all working days.

Date: 11-12-2025

SHAHNAWAZ QASIM, IPS
DIRECTOR GENERAL

Photograph



Send your news and articles to:
dcoiwanewsletter@gmail.com

Andhra Pradesh

23 December 2025

Hyderabad

Medical Device Manufacturer Found Operating Without Valid Licence in Telangana.

The Drugs Control Administration (DCA), Telangana, has taken swift regulatory action against M/s Mediblue Healthcare Pvt. Ltd., a medical device manufacturer, for operating without a valid manufacturing licence at its premises located in Sultanpur, Sangareddy District, Telangana.

Inspection and Findings.

On 23 December 2025 at around 6:00 PM, a team of Drugs Inspectors conducted a detailed inspection of the firm's premises.

The inspection was carried out under the supervision of Shri K. Dass, Deputy Director, Drugs Control Administration, Telangana.

The inspecting team comprised:

Shri T. Praveen Kumar, Drugs Inspector, Bollaram,

Shri N. Ravikiran Reddy, Drugs Inspector, Sangareddy

Shri M. Varaprasad, Drugs Inspector, Pashamylaram

Shri G. Srikanth, Drugs Inspector, Jinnaram

During the inspection, it was observed that the firm was manufacturing Class B Medical Devices, including Dialysis Kits (Sterile EO), Sterile Surgical Gowns, and Surgical Drapes, without holding a valid manufacturing licence on Form MD-5 for the said premises.

Action Taken

The firm holds a valid manufacturing licence for



a different premises located at Kukatpally, Hyderabad.

However, it was found that the same licence details were being improperly used for manufacturing activities at the Sultanpur premises without obtaining approval for change of premises or a fresh licence, which is a clear violation of Section 18(c) of the Drugs and Cosmetics Act, 1940.

Accordingly, the Drugs Inspectors have initiated seizure proceedings, and further legal action is being pursued as per the provisions of law.

Official Statement

Speaking on the occasion, Shri K. Dass, Deputy Director, Drugs Control Administration, Telangana, stated:

“The Drugs Control Administration is committed to ensuring public health and safety. Strict action will be taken against any violations of the Drugs and Cosmetics Act, 1940, without exception.”

The investigation is currently under progress, and further action will be taken based on the outcome, in accordance with the law.

Source: G Koteswar Rao

Puducherry

Former IFS Officer Arrested In Puducherry Counterfeit Drug Racket

Puducherry, December 24, 2025

In a major breakthrough in the ongoing investigation into a large-scale counterfeit drug manufacturing racket, a Special Investigation Team (SIT) of the Puducherry Police arrested former Indian Forest Service (IFS) officer G. Sathiyamoorthy on **December 24, 2025**.

The retired officer, who had opted for the Voluntary Retirement Scheme (VRS), was apprehended in Hosur, Tamil Nadu, after evading authorities for weeks.

Sathiyamoorthy is accused of assisting the main kingpin, Raja alias Velliappan, in making Goods and Services Tax (GST) payments linked to the illegal operations. Police sources revealed that during interrogation of Raja and other accused, it emerged that Sathiyamoorthy played a key role in facilitating these financial transactions, enabling the racket to continue undetected for an extended period.

The former officer was subsequently brought to Puducherry for further questioning. Reports indicate that Sathiyamoorthy has named several serving officials in the GST department in Puducherry who allegedly aided in the payments, potentially widening the scope of the probe.

Background of the Counterfeit Drug Scandal

The racket came to light in September 2025 following raids by a joint team from the Central Drugs Standard Control Organisation (CDSCO) and the Puducherry Drugs Department. Authorities seized empty capsules, tablets, packaging materials, and other items worth approximately ₹99.47 lakh from a godown in Mettupalayam industrial area.

The investigation gained momentum after disclosures from arrests in Agra, Uttar Pradesh,



where spurious drugs traced back to Puducherry-based units were uncovered. The counterfeit medicines, mimicking brands from reputed pharmaceutical companies like Sun Pharma and Lupin, were reportedly manufactured in unlicensed facilities and distributed across at least 16 states.

Key developments include:

"Seizure of advanced drug manufacturing machinery worth ₹14 crore.

Recovery of assets worth ₹2.5 crore, including gold ornaments, from Raja's residence.

Arrest of over 20 individuals so far, including Raja (the alleged mastermind), his associate Vivek, A.K. Rana, Meyyappan, and several others involved in production and distribution.

The illegal units operated without valid licenses or GST registration for years, producing look-alike versions of branded medicines that posed severe risks to public health.

Political and Investigative Ramifications

The case has sparked intense political controversy in the Union Territory. Opposition parties, including Congress and DMK, have demanded a CBI probe, alleging involvement of influential figures and potential protection under the ruling AINRC-BJP government. Lieutenant

(Continued on page 45)

Puducherry

(Continued from page 44)

Governor K. Kailashnathan recently recommended investigations by the CBI and National Investigation Agency (NIA), citing inter-state ramifications and the need for a national-level inquiry.

Financial angles are also under scrutiny, with details of transactions shared with the Enforcement Directorate (ED). Agra Police have coordinated with local authorities, highlighting the racket's nationwide reach.

Public health experts have raised alarms over the circulation of spurious drugs, which could lead to treatment failures, adverse reactions, or even fatalities. The Puducherry Drugs Control Department earlier alerted the Drugs Controller General of India (DCGI) about 34 suspected counterfeit samples detected in the local market.

Ongoing Probe and Public Safety Concerns

The SIT continues its interrogation of Sathiyamoorthy to uncover deeper connections, including any complicity from government officials. Authorities have assured stringent action against all involved, emphasizing zero tolerance for activities endangering public health.

This arrest underscores the growing menace of counterfeit pharmaceuticals in India, a market estimated to cause billions in losses annually



while jeopardizing patient safety.

As the investigation progresses, more revelations are expected, potentially exposing systemic vulnerabilities in drug regulation and taxation compliance.

Residents are advised to purchase medicines only from licensed pharmacies and report suspicious products to authorities.

The case serves as a stark reminder of the need for robust oversight in the pharmaceutical supply chain to prevent such rackets from thriving.

Source: G Koteswar Rao



Chhattisgarh

Decisive FDA Action Against Substandard and Spurious Drugs: Chhattisgarh

Illegal Drug Supply Chain Uncovered from Raipur to Sarangarh

The **Food and Drugs Administration (FDA), Chhattisgarh**, has been consistently undertaking strict surveillance and enforcement actions against the manufacture, transport, storage, and sale of spurious, substandard, and illegally circulated drugs in the State. One such significant enforcement action carried out in December 2025 has brought to light the seriousness of illegal drug movement and the possible existence of an unauthorized supply chain.

On **10 December 2025**, the Department received specific information regarding a suspicious consignment of medicines at **Nagpur Golden Transport, Raipur**. Acting promptly on the input, an inspection team was constituted for immediate verification. During the inspection, serious discrepancies were observed between the drugs mentioned in the transport documents and the actual contents of the consignment. The medicines listed in the bill were not found in the consignment, while other drugs of different types were present. These inconsistencies raised strong suspicion regarding the drugs being spurious or not of standard quality. Considering the gravity of the findings, the drugs were lawfully seized at the spot and samples were drawn and forwarded to the State Drugs Testing Laboratory, Raipur for analysis. Simultaneously, a detailed investigation was initiated to trace the actual source of the drugs, identify the supply chain, and ascertain any possible illegal activities involved in their distribution.

In continuation of the seizure action, an inspection was conducted on 16



December 2025 at **M/s Saraswati Medical Store, Sarangarh**, in the presence of the firm's proprietor, Mr. Khem Ram Bani. During the inspection, the proprietor was asked to produce valid records, purchase invoices, and documents related to the possession and sale of the seized drugs. However, no such documents could be produced at the spot. Accordingly, a panchnama was prepared in accordance with legal procedures, and a written statement of the proprietor was recorded. During the inspection, the activities of other persons present at the premises were also examined. In this sequence, the mobile phone of Mr. Vansh Kesharwani, son of Mr. Khem Ram Bani, was checked. A photograph of one of the seized drugs, **ARRCEF-AZ Tablets**, was found stored in the mobile phone, which emerged as a significant piece of digital evidence in the case. Based on this finding, the mobile phone was seized as evidence, and a written statement of the concerned person was also recorded.

To further strengthen the investigation, a lawful inspection of the proprietor's residential premises was carried

(Continued on page 47)

Chhattisgarh

(Continued from page 46)

out. During the inspection, a large quantity of various allopathic medicines was found stored at the residence, indicating that drug storage was not confined solely to the licensed business premises. However, the specific seized drug was not found at the residence. This information was immediately conveyed to the jurisdictional Drugs Inspector, and further statutory action was initiated as per the provisions of law.

Meanwhile, the analytical report received from the **State Drugs Testing Laboratory, Raipur**, significantly intensified the seriousness of the case. As per the laboratory findings, three drugs; 1. **G-CEF-AZ Tablets** (Cefixime and Azithromycin with Lactic Acid Bacillus Tablets), bearing **Batch No. GB-2440** with an **expiry date of October 2026**, manufactured by **M/s G Biotech Private Limited**, Nahan Road, Paonta Sahib, Solan, Himachal Pradesh; 2. **CUMOX-CV-625 Tablets** (Amoxicillin, Potassium Clavulanate and Lactic Acid Bacillus Tablets IP), bearing **Batch No. GCA012** with an **expiry date of March 2027**, manufactured by **M/s G.C. Healthcare**, Parwanoo, Solan, Himachal Pradesh; and 3. **ARRCEF-AZ Tablets** (Cefixime and Azithromycin with Lactic Acid Bacillus Tablets), bearing **Batch No. 2827** with an **expiry date of April 2027**, manufactured by **M/s Larrax Pharmaceuticals**, Gopal Krishna Road, Chennai. were declared Not of Standard Quality (NSQ) and Spurious. Following this confirmation, the Food and Drugs Administration, Chhattisgarh, issued immediate



alerts to the Central Drugs Standard Control Organization (CDSCO), New Delhi, as well as to all districts across the State, directing officials to maintain strict vigilance over the transportation, storage, and sale of the said drugs.

Food and Drugs Administration has appealed to the general public, licensed drug retailers, and transport agencies to promptly report any suspicious medicines or illegal activities to the Department through the designated helpline number or official email. The Department also emphasized that procurement and supply of medicines must strictly be carried out only through authorized and licensed sources. The department has reiterated its firm commitment to ensuring the availability of safe, quality, and authentic medicines to the citizens of the State and has affirmed that stringent enforcement actions against illegal drug networks will continue without compromise.

Source: Piyush Jaiswal, Chhattisgarh

Click any where to read
all the DCOIWA Newsletters



DCOIWA News

E-Newsletter

Drugs Control Officers (D) Welfare Association (Regd)



23

DCOIWA News

January 2025

74th IPC 2025 19-21 December 2025 Bengaluru

19-21 DECEMBER 2025

74th INDIAN PHARMACEUTICAL CONGRESS



IPC



B E N G A L U R U

Glimpse of 74th IPC 2025 19-21 December 2025, Bengaluru



Glimpse of 74th IPC 2025 19-21 December 2025, Bengaluru



Glimpse of 74th IPC 2025 19-21 December 2025, Bengaluru



Glimpse of 74th IPC 2025 19-21 December 2025, Bengaluru



A glimpse of retired and serving Delhi Drugs Control Officers on 29.12. 2025 during pre-retirement get together of Mr KR Chawla (not in picture) who will superannuate on 31.12.2025



Drugs Abuse Awareness Program Elumathur, Tamil Nadu

On invitation from the Principal, Government Arts and Science College, Modakkurichi, Erode, Tamil Nadu for Drugs Awareness Program to the Students as part of NCORD activities, Mr. Sakthivel E, Drugs Inspector, Erode I Range presented a Talk on Drugs Abuse on 31/12/2025



Send your news and articles to:
dcoiwanewsletter@gmail.com



Chintan Shivir on Pharmaceutical Industry At Chandigarh By Pharmexcil

Organized by:



Chintan Shivir on **PHARMACEUTICAL INDUSTRY**

December 17, 2025 at Chandigarh
Hotel: The Lalit, Chandigarh
IT Park Rd, Sector 13 Chandigarh 160101

**Industry Interaction with Key Stakeholders on Regulatory
Implementing the Revised GMP Guidelines for
Enhanced Regulatory Compliance**

Speakers



Shri R Chandrashekar
Jt. DCGL, CDSCO,
Ministry of Health and Family Welfare
Government of India



Shri. Namit Joshi
Chairman
PHARMEXCIL



Shri Lalit Goel
Drugs Controller
Food and Drugs Administration
Haryana



Shri Sanjeev Garg
Joint Commissioner (Drugs)
and State Drug Controller for
FDA (Punjab)



Shri. Nipun Jain
Chairman – IPHEX
CoA Member –
PHARMEXCIL



Shri. R L Sharma
President
Haryana Pharmaceutical
Manufactures Association



Dr. Rajesh Gupta
President
Himachal Drugs
Manufacturers Association



Mr. Amit Chawla
CoA Member
PHARMEXCIL

Contact Us:

Kamal Bhardwaj

rodelhi@pharmexcil.com +91 11-45062550

Chintan Shivir on Pharmaceutical Industry At Chandigarh By Pharmexcil



Visit at Asstt. Drugs Controller Officer of DCA Cuttack on 17-12-2025**Dr.K . Sridhar, a subject expert with laboratory analysts of Nagaland at Kohima during week long training program in December 2025**

Visit to state Drugs Controller Officer of DCA Odisha on 15-12-2025**Greeting Shri. R.P. Chowdhury, President, AIDCOC on his superannuation at thane, Mumbai****Smt Kanchan Sinha Ex Drugs Controller, Tripura and DCOIWA CEC member and Drugs Controller of Rajasthan Sh. Ajay Phatak**



Pallavi Memorial Trust

48th BIRTHDAY

Date: 12th December, 2025

Smt. Banoth Pallavi

Deputy Director

Drugs Control Administration, Govt. of Telangana

PALLAVI MEMORIAL TRUST

Regd. No. 17/2020

15-21-150/6, Kukatpally, Hyderabad, (T.S.) India.



1977 - 2019



G. Koteswar Rao

National President, DCO(I)WA

Chairman, PALLAVI MEMORIAL TRUST

8121296397, inspectordrugs@gmail.com



Dr. A. Ramkishan, Member
DDC, CDSCO
Ph: 8447261567



G. Ramdhan, Member
JDC, DCA TS
Ph: 9666984242



N. Narsaiah, Member
ADC, DCA TS
Ph: 8179373228

Click any where to read all the DCOIWA Newsletters



E-Newsletter

DCOIWA News

Drugs Control Officers (I) Welfare Association (Regd)



23

Best wishes on the retirement: Sh. K R Chawla



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoicwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

Organizing Secretary:

Mr. Rakesh Dahiya
Cell: 99116 00019, Haryana

Vice-Presidents:

Mr. Lalit Kumar Goel
Cell: 70567 02999, Haryana

Dr. M. Dhilip Kumar
Cell: 9840071715, Tamilnadu

Mr. D. R. Gahane
Cell: 98928 32289, Maharashtra

Mr. V. D. Dobarja
Cell: 98790 60666, Gujarat

Dr. A. Ramkishan
Cell: 63057 50926, CDSCO

Dr. Manish Kapoor
Cell: -9418081270 - Himachal Pradesh

Mrs. Kanchan Sinha
Cell: 9774548986 - Tripura

Joint Secretaries:

Mr. Rajkumar V. Zadbuke
Cell: 9892827738 - Maharashtra

Dr. S. Umesh
Cell: 94480 54321 - Karnataka

Mr. Pooran Chand
Cell: 9760366100 - Uttar Pradesh

Mrs. Dipika Chauhan
Cell: 7990351251 - Gujarat

Mr. Chandan Kumar Giri
Cell: 8895478543 - Odisha

Mr. Amit Kumar Bansal
Cell: 9198463261 - Uttar Pradesh

Mr. Biswajit Talukdar
Cell: 7086084833 - Assam

Treasurer:

Dr. Parmanand Verma
Cell: 9977177574 - Chhattisgarh

EC Members:

Dr. E. Ananda Kirouchenane
Cell: 9443959680 - Puducherry

Mr. Venkatesh Sinari
Cell: 9850608501 - Goa

Mrs. Garima Sharma
Cell: 9418086497 - Himachal Pradesh

Mr. M. N. Sridhar
Cell: 94441 17139 - Tamilnadu

Mr. Ashutosh Kumar Chaube
Cell: 9415632071 - Uttar Pradesh

Dr. Mahalakshmy .R
Cell: 9497004156 - Kerala

Dr. Zaffer Ahmad
Cell: 7298009092 - Jammu & Kashmir

Mr. Irap T. D. Toi
Cell: 9233323204 - Meghalaya

Mr. Ibom Ete
Cell: 8414819858 - Arunachal Pradesh

Mr. Neeraj Kumar
Cell: 9458900286 - Uttarakhand

Dr. Mrinal Kanti Sarkar
Cell: 8974822360 - Tripura

Mr. Tapan Choudhry
Cell: 9230610226 - West Bangal

Lt. No. DCOIWA/231225/08

Date: 31st December 2025
Place: Hyderabad.

To
Shri. K. R. Chawla,
Deputy Drugs Controller and Controlling Authority,
Delhi.



Respected Sir,

On behalf of the Drugs Control Officers India Welfare Association (DCOIWA) and on my own behalf, I convey my heartiest congratulations to you on the occasion of your retirement on 31st December 2025.

Your illustrious career as the Deputy Drugs Controller and Controlling Authority, Delhi, stands as a testimony to your dedication, professionalism, and steadfast commitment to upholding the highest standards of drug regulation and public health protection. Your visionary leadership, administrative excellence, and principled decision-making have significantly strengthened the regulatory system and have earned you the respect and admiration of your colleagues and peers across the nation.

As you complete your distinguished journey in public service, we place on record our sincere appreciation for your invaluable contributions and extend our best wishes for a happy, healthy, and fulfilling post-retirement life, filled with peace, joy, and continued success in all your future endeavors.

With warm regards and respectful salutations,

Yours sincerely,

G. Koteswar Rao
National President
Drugs Control Officers India Welfare Association



H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800, 9977177574.



Best wishes on the retirement: Smt. Purnima Kabu



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoiwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

- Organizing Secretary: Mr. Rakesh Dahiya
Vice-Presidents: Mr. Lalit Kumar Goel, Dr. M. Dhillip Kumar, Mr. D. R. Gahane, Mr. V. D. Dobarja, Dr. A. Ramkishan, Dr. Manish Kapoor, Mrs. Kanchan Sinha
Joint Secretaries: Mr. Rajkumar V. Zadbuke, Dr. S. Umesh, Mr. Pooran Chand, Mrs. Dipika Chauhan, Mr. Chandan Kumar Giri, Mr. Amit Kumar Bansal, Mr. Biswajit Talukdar
Treasurer: Dr. Parmanand Verma
EC Members: Dr. E. Ananda Kirouchenane, Mr. Venkatesh Sinari, Mrs. Garima Sharma, Mr. M. N. Sridhar, Mr. Ashutosh Kumar Chaube, Dr. Mahalakshmy .R, Dr. Zaffer Ahmad, Mr. Irap T. D. Toi, Mr. Ibom Ete, Mr. Neeraj Kumar, Dr. Mrinal Kanti Sarkar, Mr. Tapan Choudhry

Lt. No. DCOIWA/231225/07

Date: 31st December 2025
Place: Hyderabad.

To
Smt. Purnima Kabu
State Drugs Controller,
Jammu & Kashmir.



Respected Madam,

On behalf of the Drugs Control Officers India Welfare Association (DCOIWA) and on my own behalf, I extend my heartiest congratulations to you on the occasion of your superannuation on 31st December 2025.

Your distinguished career as the State Drugs Controller, Jammu & Kashmir, has been marked by dedicated service, professional integrity, and unwavering commitment to strengthening drug regulation and safeguarding public health.

As you conclude this important chapter of public service, we place on record our deep appreciation for your valuable contributions and extend our best wishes for a healthy, peaceful, and fulfilling post-retirement life, enriched with happiness and new pursuits.

With warm regards and respectful salutations,

Yours sincerely,

[Signature]

G. Koteswar Rao
National President
Drugs Control Officers India Welfare Association



H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800,9977177574.



23



Best Wishes on retirement



The DCOIWA family extends its best wishes for the future endeavours of the following officer who have recently retired. May God bless them with all happiness and healthy life.



Sh. K R Chawla
Deputy Drugs
Controller &
Controlling
Authority Delhi



**Mrs. Purnima
Kabu**
State Drugs
Controller J&K



Congratulations

Laughter dose



At a conference, a doctor was preparing to give his speech on a new form of treatment that could save many lives.

He had a terrible memory and got nervous quite easily, so he writes his notes beforehand.

When he finally gets on stage to present his discovery is horrified to realize he can't read any of his notes!

After a moment of silence, he asks, **“Is there a Pharmacist in the audience?”**

Source: **PK Jaggi**, Co-Editor



New Members of DCOIWA

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Mr. Nagaraj KS
Asst. Director

ID No. : 1679/TS/2025
Phone No. : 9032003579
B Group : -
Address : Drugs Control Administration,
Vengalrao Nagar,
Hyderabad.


Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Dr. Subhash C Mandal
Asst. Drugs Controller (Retd)

ID No. : 1680/WB/2025
Phone No. : 9830136291
B Group : AB+ ve
Address : Nalanda, Fartabad Amtola,
Behind Khelaghar, P.O. Garia,
Kolkata - 700084, West Bengal.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com




Mr. Gajanand Kumawat
Drugs Control Officer

ID No. : 1681/RJ/2025
Phone No. : 8107259204
B Group : O- ve
Address : District Food Safety & Drug Control,
CMHO Office, Swasthya Bhawan,
Kudli, Jaipur- Jhunjhunu Bypass Road,
Sikar, Rajasthan - 332024



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Dr. Rajeev Singh Raghuvanshi
Drug Controller General (India)

ID No. : 1682/CDSO/2025
Phone No. : 8800991287
B Group : + ve
Address : CDSO Headquarters,
FDA Bhawan, Kotla Road,
New Delhi - 110002


Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Mrs. Monalisha Mallick
Drugs Inspector

ID No. : 1683/OD/2024
Phone No. : 7377212034
B Group : O+ ve
Address : Health & Family Welfare,
O/o Drugs Inspector, Ranipatna,
Nayabazar, Sahadevkhunta,
Balasore - 756001, Odisha.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Mr. Babulal Birdhariya
Drugs Inspector

ID No. : 1684/MP/2024
Phone No. : 9770492859
B Group : AB+ ve
Address : Food and Drugs Administration,
District Hospital Campus,
Morena - 476001, Madhya Pradesh.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Ms. Sharmila Sahoo
Drugs Inspector

ID No. : 1685/OD/2024
Phone No. : 8144826244
B Group : O+ ve
Address : Directorate of Drugs Control,
Bhubanwshar - 751017
Odisha



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Mr. Chandan Kumar Sahoo
Drugs Inspector

ID No. : 1686/OD/2024
Phone No. : 8847839990
B Group : B+ ve
Address : O/o Drugs Inspector,
Plot No. 879, Sector-10,
CDA, PS: CDA Phase-II,
Cuttack, Odisha - 753014


Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Mr. Hitesh Kumar Behera
Drugs Inspector

ID No. : 1687/OD/2025
Phone No. : 8984241240
B Group : O+ ve
Address : O/o Drugs Inspector,
Puri Range - II, Plot No. 803,
Sarodaya Nagar, Puri - 752002
Odisha.


Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Mr. Manoj Kumar Mahapatra
Drugs Inspector

ID No. : 1688/OD/2025
Phone No. : 9356684535
B Group : O+ ve
Address : Drugs Control Administration,
C-99, Sector-6, Rourkela - 769002
Odisha.


Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Mr. Dipti Ranjan Mohapatra
Drugs Inspector

ID No. : 1689/OD/2025
Phone No. : 9348190177
B Group : O+ ve
Address : Bhadrak Range - II,
Drugs Control Organization,
Charampa - 756101
Odisha.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoidcwa@gmail.com | Website: www.dcoiwa.com



Mr. Deepak Kumar Singh
Drugs Inspector

ID No. : 1690/OD/2025
Phone No. : 8249810383
B Group : O+ ve
Address : Drugs Control Administration,
O/o Drugs Inspector, Barghar Range,
Brahmachari, Gurudwara Chowk,
Barghar - 78028, Odisha.


Signature of President

New Members of DCOIWA

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mr. Prasanjeet Mohanty
Drugs Inspector
ID No. : 1691/OD/2025
Phone No. : 9337902897
B Group : O+ ve
Address : Drugs Control Administration,
O/o Drugs Inspector, Bargharh Range II,
Barhamchhari, Gurudwara Chowk,
Bargharh - 768028, Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Mr. Sachin Nayak
Drugs Inspector
ID No. : 1692/OD/2025
Phone No. : 8280309576
B Group : B+ ve
Address : Drugs Control Administration,
O/o Drugs Inspector, Jharsuguda Range,
Near District Court Complex,
Jharsuguda - 768204, Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Mr. Rolance Bhutia
Drugs Inspector
ID No. : 1693/OD/2025
Phone No. : 9337945953
B Group : O+ ve
Address : Drugs Control Administration,
O/o Drugs Inspector,
Jogdhari, Jagatsinghpur - 754103
Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Mr. Ardhendu Sekhar Manasingh
Drugs Inspector
ID No. : 1694/OD/2025
Phone No. : 7855817098
B Group : A+ ve
Address : Directorate of Drugs Control,
Khordha Range,
Bhubaneswar - 752057


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mr. Dibya Ranjan Naik
Drugs Inspector
ID No. : 1695/OD/2025
Phone No. : 7978507181
B Group : AB- ve
Address : Directorate of Drugs Control,
Near Chhapupadia, Phanipur,
Mayurbhanj - 757002, Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Mr. Deepak Kumar Hati
Drugs Inspector
ID No. : 1696/OD/2025
Phone No. : 9090340250
B Group : A+ ve
Address : Directorate of Drugs Control,
Plot No. 11/4C/1447, Lane - 2,
Sector-II, Cuttack - 753015
Odisha


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Dr. Satish Kanhar
Drugs Inspector
ID No. : 1697/OD/2025
Phone No. : 9437694459
B Group : O+ ve
Address : Directorate of Drugs Control,
Plot No. 3C-879, Sector-10, CDA,
Abhinava Bidanasi, P.S. CDA Phase-II,
Cuttack - 753014, Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Mr. Pabitra Ranjan Kar
Drugs Inspector
ID No. : 1698/OD/2025
Phone No. : 9438833852
B Group : O+ ve
Address : H & FW Department,
Office of the DDC,
Western Zone,
Sambalpur - 768006, Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mrs. Manjari Tirkey
Drugs Inspector
ID No. : 1699/OD/2025
Phone No. : 9777837885
B Group : O+ ve
Address : H & FW Department,
Office of the DDC,
Western Zone, Sambalpur,
Kainsir - 768004, Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Dr. Shakuntala Dhurva
Drugs Inspector
ID No. : 1700/OD/2025
Phone No. : 6372941643
B Group : O+ ve
Address : O/o Drugs Inspector, Mahesdihi,
Near Govt. Womens College,
Sundhargharh - 770001, Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Ms. Supriya Behera
Drugs Inspector
ID No. : 1701/OD/2025
Phone No. : 7735224715
B Group : AB+ ve
Address : O/o Drugs Inspector,
Near EVM Godown,
Paralakhemundi - 761200
Odisha.


Signature of President

DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION
H.Q. 15-21-150/6, New Balaji Nagar, Kukatapally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Ms. Sangita Pattanayak
Drugs Inspector
ID No. : 1702/OD/2025
Phone No. : 7605930020
B Group : O+ ve
Address : Drugs Control Administration,
BBSR-V Range, Plot No. M-79,
Baramunda Housing Board Colony,
Khandagiri, Bhubaneswar - 751003


Signature of President


New Members of DCOIWA

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Ms. Jayashree Patra
Drugs Inspector

ID No. : 1703/OD/2025
Phone No. : 9556042433
B Group : B+ ve
Address : Drugs Control Administration,
Balasore Sadar Range,
Rani Patna, Nayabazar,
Sahadevkunta - 756001, Odisha,



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mr. Arun Kumar Naik
Drugs Inspector

ID No. : 1704/OD/2025
Phone No. : 7430813873
B Group : O+ ve
Address : Directorate of Drugs Control,
O/o Drugs Inspector,
Tikar Gumura, Ghuntur 758002,
Odisha,



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mr. Prasanta Sethy
Drugs Inspector

ID No. : 1705/OD/2025
Phone No. : 9778840857
B Group : AB+ ve
Address : H & FW Dept. of Govt. Odisha,
O/o Drugs Inspector, Ganjam-II,
Chatrapur - 761020, Odisha.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Ms. Rojalin Samal
Drugs Inspector

ID No. : 1706/OD/2025
Phone No. : 9777742147
B Group : O- ve
Address : Drugs Control Administration,
O/o Drugs Inspector, BBSR- IV Range,
Plot. No. 332 & 332/905, Satya Nagar,
Karvel Nagar, BBSR - 751007, Odisha.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mrs. Padmini Kanhar
Drugs Inspector

ID No. : 1707/OD/2025
Phone No. : 7978715343
B Group : AB+ ve
Address : H & FW Dept. of Govt. Odisha,
Ganjam Range-III,
Bhanjanagar- 761126, Odisha.


Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Ms. Manisha Ahirwar
Drugs Inspector

ID No. : 1708/MP/2025
Phone No. : 9243965718
B Group : -
Address : O/o Deputy Director,
Food And Drugs Administration,
Dist. Seoni - 480661
Madhya Pradesh



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com




Mr. Saurabh Gautam
Drugs Inspector

ID No. : 1709/OD/2025
Phone No. : 7609889420
B Group : B+ ve
Address : H & FW Dept.
Drugs Control Administration,
Angul - II Range,
Angul - 759122, Odisha


Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mr. Ankush Kumar Agrawal
Drugs Inspector

ID No. : 1710/OD/2025
Phone No. : 7682984467
B Group : B+ ve
Address : O/o Drugs Inspector,
Bolangir - II Range, NCC Colony,
Sagarpada, Bolangir - 767001
Odisha.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mrs. Bhagyashree Patra
Drugs Inspector

ID No. : 1711/OD/2025
Phone No. : 6371591829
B Group : B+ ve
Address : Drugs Control Administration,
Plot No. 3C - 879, CDA Sector-10,
Abhinavbidanasi, Cuttack - 753014
Odisha.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Ms. Dharitri Sabar
Drugs Inspector

ID No. : 1712/OD/2025
Phone No. : 8597220531
B Group : AB+ ve
Address : Drugs Control Administration,
H&FW Dept. O/o Drugs Inspector,
Ashirvad Colony, Mirganguda,
Nabarangpur - 764059, Odisha.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Ms. Tikeswari Majhi
Drugs Inspector

ID No. : 1713/OD/2025
Phone No. : 9178788495
B Group : B+ ve
Address : Drugs Control Administration,
O/o Drugs Inspector,
Patabhadi, Sonepur,
Dist. Subarangpur - 767017
Odisha.



Signature of President

**DRUGS CONTROL OFFICERS
(I) WELFARE ASSOCIATION**
H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA.
(Regd.No. 634 of 2022)
E-mail: dcoicdwa@gmail.com | Website: www.dcoiwa.com



Mr. Nakhtra Bhusan Nayak
Drugs Inspector

ID No. : 1714/OD/2025
Phone No. : 9556291877
B Group : O+ ve
Address : O/o Drugs Inspector,
Koraput Range, NH-26,
Infront of LIC Office, Jeypore,
Dist. Koraput - 764004, Odisha.


Signature of President

New Members of DCOIWA

 <p>DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA. (Regd.No. 634 of 2022) E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com</p>  <p>Mr. Binayak Dalabehera Drugs Inspector</p> <p>ID No. : 1715/OD/2025 Phone No. : 8275111686 B Group : O+ ve Address : Drugs Control Administration, Plot No. 3D/1200, Sector-10, CDA Cuttack, Abhinavabidanashi - 753014, Odisha.</p> <p><i>[Signature]</i> Signature of President</p>	 <p>DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA. (Regd.No. 634 of 2022) E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com</p>  <p>Mr. Deepak Kumar Jena Drugs Inspector</p> <p>ID No. : 1716/OD/2025 Phone No. : 6296498189 B Group : O+ ve Address : Drugs Control Administration, O/o Drugs Inspector, Charampa, Rhadrak - 756101, Odisha.</p> <p><i>[Signature]</i> Signature of President</p>	 <p>DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA. (Regd.No. 634 of 2022) E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com</p>  <p>Mr. Amit Maity Drugs Inspector</p> <p>ID No. : 1717/OD/2025 Phone No. : 8984991033 B Group : A+ ve Address : Health & Family Welfare Dept. O/o Drugs Inspector, Cuttack - IV Range, Cuttack - 753014 Odisha.</p> <p><i>[Signature]</i> Signature of President</p>	 <p>DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA. (Regd.No. 634 of 2022) E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com</p>  <p>Mrs. Sarala Nayak Drugs Inspector</p> <p>ID No. : 1718/OD/2025 Phone No. : 8800931808 B Group : B+ ve Address : H & FW Dept. Drugs Control Administration, O/o Drugs Inspector, Rayagada, Near RMC Gate, Kottlaguda - 765002 Odisha.</p> <p><i>[Signature]</i> Signature of President</p>
	 <p>DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA. (Regd.No. 634 of 2022) E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com</p>  <p>Mr. Aswini Kumar Gond Drugs Inspector</p> <p>ID No. : 1719/OD/2025 Phone No. : 9302584448 B Group : O+ ve Address : H & FW Dept. Drugs Control Administration, O/o Drugs Inspector, Sai Nagar Lane - I, Duarsuni, Bhawanipatna, Kalanandi - 766002 Odisha.</p> <p><i>[Signature]</i> Signature of President</p>	 <p>DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION H.Q. 15-21-150/6, New Balaji Nagar, Kukatpally, Hyderabad (T.S), INDIA. (Regd.No. 634 of 2022) E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com</p>  <p>Dr. Santosh Kumar Panda Drugs Inspector</p> <p>ID No. : 1720/OD/2025 Phone No. : 7978195146 B Group : O+ ve Address : Drugs Control Organization, At Ganesh Nagar, 3rd Lane, Berhampur - 760002, Odisha.</p> <p><i>[Signature]</i> Signature of President</p>	

How to become a member

[Register Online](#)

[Download Form](#)




23

CDSCO

States


NSQ List: November 2025

Click any where to read
all the DCOIWA Newsletters



DCOIWA News E-Newsletter

Drugs Control Officers (I) Welfare Association (Regd)



Click below links to download:

[NSQ: November 2025 CDSCO](#)

[NSQ: November 2025 STATES](#)

[NSQ: Year wise](#)

Source: CDSCO Website



Sub-Standard Drugs



Send your news and articles to:
[**dcoiwanewsletter@gmail.com**](mailto:dcoiwanewsletter@gmail.com)



Important Links



Important links

[PG Portal](#)

[CDSCO](#)

[SUGAM Portal](#)

[Online System for Medical Devices](#)

[State FDAs Portal](#)

[NPPA](#)

[Jan Aushadhi](#)

[Pharmexcil](#)

[FSSAI](#)

[eCourts](#)

[Pharma Sahi Daam](#)

[National Medical Commission](#)

[Clinical Establishment](#)

[Pharmacy Council of India](#)



Important short notes for Industry and Regulators
By Lalit Kr. Goel, FDA Haryana



IMPORTANT
Short Notes
for
Industry and Regulators
by Lalit Kr. Goel FDA Haryana

To read click anywhere in the picture

Key Notes on Revised Schedule M: Compilation
By Rakesh Dahiya, FDA Haryana



The Health Master
Key Notes
Revised
Schedule M
Compilation
By Rakesh Dahiya, FDA Haryana

To read click anywhere in the picture

Ketamine: Understanding its Classification and Regulations in India

by
Lalit Kr. Goel
State Drugs Controller,
FDA Haryana



Ketamine

[Ketamine](#), a well-known anaesthetic and analgesic drug, has garnered attention not only for its medical applications but also for its classification under regulatory frameworks.

Understanding Ketamine's Classification

The Categorization Process

- Ketamine's classification as a psychotropic substance was formalized through notification no. **S.O. 311(E) dated 10.02.2011**, issued by the Department of Revenue, Ministry of Finance, Government of India.

Ketamine also classifies as small quantity (10gm) and commercial quantity (500gm) under [NDPS Act 1985](#) vide notification No. **S.O. 1430(E) dated 21.06.2011 issued by the Department of Revenue, Ministry of Finance, Government of India.**

Scheduled X Drug Declaration:



Further, it was declared as a [Scheduled X](#) drug under notification no. **GSR 724(E) dated 07.11.2013, issued by the Department of Health, Ministry of Health and Family Welfare, Government of India.**

Regulatory Requirements for Ketamine

Mandatory Label Warnings

Labelling Mandates

Both warnings for psychotropic substances and **Scheduled X** drugs

(Continued on page 71)

Ketamine: Understanding its Classification and Regulations in India

by
Lalit Kr. Goel
State Drugs Controller,
FDA Haryana



(Continued from page 70)

are obligatory to be printed on the label of **ketamine**.

NRx should be printed in red colour on the top left corner on the label.

Licensing Regulations

Necessity of Separate License

Manufacturing and sale of ketamine drug require a separate license under **Schedule X**, as mandated by regulatory authorities.

Ketamine is not Essential Narcotics Drugs (END) for the purpose of [Recognized Medical Institute](#) (RMI).

Compliance and Enforcement

Ensuring Adherence to Regulations

Regulatory Oversight



Regulatory bodies enforce stringent measures to ensure compliance with labelling requirements and licensing regulations for ketamine

Monitoring Supply Chains

Inspection and monitoring of supply chains are conducted to verify adherence to regulatory mandates concerning ketamine

[Click for more article of the Author](#)

**Send your news and articles to:
dcoiwanewsletter@gmail.com**



23

FAQs



by
Lalit Kr. Goel
State Drugs Controller,
FDA Haryana



To read all FAQs on various topics, Click the below links

[FAQs – on Blood Pressure Monitoring Devices](#)

[FAQs – on Alcohol \(in Pharma Industry\)](#)

[Blood Centre \(Bank\) – requirements at a glance](#)

[FAQs on – Cosmetics Rules 2121](#)

[FAQs – on Mouthwash](#)

[Fee structure: All types of drugs licenses](#)

[FAQs – on Ear Drops](#)

[FAQs – on Drug Permission in Brand or Generic Name](#)

[FAQs – on Disinfectants \(Series-2\)](#)

[Gist of Notification 25th September 2121: Medical Oxygen](#)

[Salient features of Supreme Court order dated 28.08.2121](#)

[Pharmacopoeial status of Blood and its components](#)

[Difference between Sanitizer and Disinfectant](#)

[FAQs on Legal Metrology & Blood Bags](#)

[FAQs on Sanitizer, N95 Mask & Digital Thermometer](#)

[FAQs on Medical Oxygen](#)

[FAQs – on Cosmetics \(Series-1\)](#)

[FAQs – on Blood Bank \(Series-1\)](#)

[FAQs – on Blood Bank \(Series-2\)](#)

[FAQs – on Blood Bank / Centre \(Series-3\)](#)

[FAQs on Medical Devices Rules, 2117](#)

[FAQs about New Drug, Banned drugs etc.](#)

[FAQs on Disinfectant \(Series-1\)](#)

[FAQs – on Disinfectants \(Series-2\)](#)

[FAQs – On ‘Good Night’, ‘All Out’, ‘Hit’ and ‘Harpic’ etc.](#)

[FAQs – on Ranitidine tablets and injections in India](#)

[FAQs – On Narcotic Drugs, Brand Names of drug \(G.S.R. no. 828 \(E\)\)](#)



Schedules: All types of Medical Devices



Schedules

Compiled by
Rakesh Dahiya
FDA Haryana



For Schedules on following topics
Click below links

1

Schedules

Schedules: All types of Medical Devices under Medical Devices Rules 2017

As per Medical Devices Rules 2017 we have provided all the Schedules introduced in these rules, Click below links for more information:

First Schedule – Parameters for classification of medical devices and in vitro diagnostic medical devices

[First-Schedule](#)

Second Schedule – Fee payable for licence, permission and registration certificate

[Second-Schedule](#)



Third Schedule – Documents required for registration of Notified Body, its duties and functions.

[Third-Schedule](#)

Fourth Schedule – Documents required for grant of licence to manufacture for sale or for

(Continued on page 74)



Schedules: All types of Medical Devices



Schedules

Compiled by
Rakesh Dahiya
FDA Haryana



For Schedules on following topics
Click below links

2

Schedules

distribution or import.

[Fourth-Schedule](#)

Fifth Schedule – (QMS) Quality Management System for medical devices and in vitro diagnostic medical devices.

[Fifth-Schedule](#)

Sixth Schedule – Post approval change.

[Sixth-Schedule](#)

Seventh Schedule – Requirements for permission to import or manufacture investigational medical device for conducting clinical investigation.

[Seventh-Schedule](#)

Eight Schedule – Exemptions.

[Eighth-Schedule](#)

Compiled by:

[Rakesh Dahiya](#)

Asstt. State Drugs Controller

[FDA Haryana](#)

[Click here for more articles of the Author](#)



23

DCOIWA News

January 2025

Pharmaceuticals

Important Notifications



भारत का राजपत्र
The Gazette of India

Important Notifications

Compiled by
Rakesh Dahiya
FDA Haryana



For notifications on following topics
Click below links

[Banned Drugs](#)

[EC Act](#)

[Blood Bank / Centre](#)

[General](#)

[Cosmetics](#)

[Homoeopathic](#)

[COTPA](#)

[Hospital – RMI](#)

[DPCO / NPPA](#)

[Medical Devices](#)

[Drug Rules](#)

[NDPS Act](#)

[Drugs Act](#)

[New Drugs](#)

[DMROA](#)

[Testing Laboratories](#)

Latest Notifications



Notification S.O. 6091(E) dt 29-12-2025

S.O. 6091(E) dt 29-12-2025 Banned drug 26A Prohibits the manufacture, sale and distribution of all oral formulation containing Nimesulide above 100 mg in immediate release dosage form with immediate effect

BANNED

THE GAZETTE OF INDIA : EXTRAORDINARY

[PART II—SEC. 3(ii)]

MINISTRY OF HEALTH AND FAMILY WELFARE

(Department of Health and Family Welfare)

NOTIFICATION

New Delhi, the 29th December, 2025

S.O. 6091(E).—Whereas the Central Government is satisfied that the use of all oral formulations containing Nimesulide above 100 mg in immediate release dosage form are likely to involve risk to human beings and that safer alternatives to the said drug is available;

And, whereas, the Central Government is satisfied that it is necessary and expedient in the public interest to prohibit the manufacture, sale and distribution of the said drug in the country for human use;

Now, therefore, in exercise of the powers conferred by section 26A of the Drugs and Cosmetics Act, 1940 (23 of 1940), and after consultation with the Drugs Technical Advisory Board, the Central Government, hereby prohibits the manufacture, sale and distribution of the following drug, with immediate effect, namely:-

“All oral formulations containing Nimesulide above 100 mg in immediate release dosage form.”

[F. No. X.11035/100/2024-DRS]

HARSH MANGLA, Jt. Secy.



23

Latest Notifications



Notification S.O. 927(E) dt 29-12-2025

GSR 927(E) dt 29-12-2025 Draft Notification Omission of word Syrup from Schedule K, Sr. No. 13 under the column Class of drugs

[GSR 927\(E\) dt 29-12-2025 Draft notification Omission of word Syrup from Schedule K, Sr. No. 13 under the column Class of drugs](#)

Click any where to read
all the DCOIWA Newsletters



DCOIWA News E-Newsletter

Drugs Control Officers (I) Welfare Association (Regd)

Upcoming Events

UPCOMING EVENTS

**2026****April-2026**

PharmaTech Expo Chandigarh

Date: April 09-11, 2026
Location: Chandigarh, India

Description: PharmaTech Expo is one of the largest pharma exhibitions in India and is a place for thousands of people from the business to share their experiences related to products, customers, business, and sales. This pharmaceutical and lab expo brings together people from across the globe to one destination. It is one of the biggest B2B trade shows of the sector that involves people from the healthcare and pharma machinery industries to participate and share innovation related to advanced technologies in the pertinent sector.

It will showcase pharma products, machinery, and technological innovation to buyers from various countries, including India, China, the USA, & Germany, which are major markets for this sector. This event will surely give you a huge platform to establish and enhance your business by meeting active suppliers looking for collaboration with the Indian pharma and healthcare market. Meeting new investors and fellow businessmen from the same fraternity would definitely be a win-win situation for both parties. If you are from the pharmaceuticals and healthcare industry and want to explore the involution of business, come and be a part of this mega pharma trade fair.

[Click for more details](#)



Send your news and articles to:
[**dcoiwanewsletter@gmail.com**](mailto:dcoiwanewsletter@gmail.com)





23

Condolence Message



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

- Organizing Secretary:**
Mr. Rakesh Dahiya
Cell: 99116 00019, Haryana
- Vice-Presidents:**
Mr. Lalit Kumar Goel
Cell: 70567 02999, Haryana
- Dr. M. Dhilip Kumar**
Cell: 9840071715, Tamilnadu
- Mr. D. R. Gahane**
Cell: 98928 32289, Maharashtra
- Mr. V. D. Dobarja**
Cell: 98790 60666, Gujarat
- Dr. A. Ramkishan**
Cell: 63057 50926, CDSCO
- Dr. Manish Kapoor**
Cell: -9418081270 - Himachal Pradesh
- Mrs. Kanchan Sinha**
Cell: 9774548986 - Tripura
- Joint Secretaries:**
Mr. Rajkumar V. Zadbuke
Cell: 9892827738 - Maharashtra
- Dr. S. Umesh**
Cell: 94480 54321 - Karnataka
- Mr. Pooran Chand**
Cell: 9760366100 - Uttar Pradesh
- Mrs. Dipika Chauhan**
Cell: 7990351251 - Gujarat
- Mr. Chandan Kumar Giri**
Cell: 8895478543 - Odisha
- Mr. Amit Kumar Bansal**
Cell: 9198463261 - Uttar Pradesh
- Mr. Biswajit Talukdar**
Cell: 7086084833 - Assam
- Treasurer:**
Dr. Parmanand Verma
Cell: 9977177574 - Chhattisgarh
- EC Members:**
Dr. E. Ananda Kirouchenane
Cell: 9443959680 - Puducherry
- Mr. Venkatesh Sinari**
Cell: 9850608501 - Goa
- Mrs. Garima Sharma**
Cell: 9418086497 - Himachal Pradesh
- Mr. M. N. Sridhar**
Cell: 94441 17139 - Tamilnadu
- Mr. Ashutosh Kumar Chaube**
Cell: 9415632071 - Uttar Pradesh
- Dr. Mahalakshmy .R**
Cell: 9497004156 - Kerala
- Dr. Zaffer Ahmad**
Cell: 7298009092 - Jammu & Kashmir
- Mr. Iarap T. D. Toi**
Cell: 9233323204 - Meghalaya
- Mr. Ibom Ete**
Cell: 8414819858 - Arunachal Pradesh
- Mr. Neeraj Kumar**
Cell: 9458900286 - Uttarakhand
- Dr. Mrinal Kanti Sarkar**
Cell: 8974822360 - Tripura
- Mr. Tapan Choudhry**
Cell: 9230610226 - West Bengal



Date: 13 December 2025
Place: Hyderabad

Condolence Message

It is with profound grief and deep sorrow that we inform the sad demise of Mr. Amith Kumar, Drugs Inspector, Jharkhand. Despite the best medical care and several sincere efforts made by the doctors, we could not save him. He breathed his last today at Apollo Hospital, New Delhi.

On behalf of the Drugs Control Officers India Welfare Association (DCOIWA), I extend my heartfelt condolences to the bereaved family, friends, and colleagues of Mr. Amith Kumar. His untimely passing is an irreparable loss to the Drugs Control fraternity and the public service at large. He will always be remembered for his dedication, sincerity, and commitment to his duties.

May the Almighty grant eternal peace to the departed soul and give strength and courage to the family to bear this immense loss.

With deepest condolences,

G. Koteswar Rao
President
Drugs Control Officers India Welfare Association

H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800, 9977177574.

Prayer meeting



DRUGS CONTROL OFFICERS (I) WELFARE ASSOCIATION

(Regd.No. 634 of 2022)

E-mail: dcoidcwa@gmail.com Website: www.dcoiwa.com

Honorary President
Dr. HEMANT G. KOSHIA
Cell: 99784 05054 - Gujarat

President
G. KOTESHWAR RAO
Cell: 8121296397 - Telangana

General Secretary
BALDEV CHOUDHARY
Cell: 8094357800 - Rajasthan

Organizing Secretary:

Mr. Rakesh Dahiya
Cell: 99116 00019, Haryana

Vice-Presidents:

Mr. Lalit Kumar Goel
Cell: 70567 02999, Haryana

Dr. M. Dhilip Kumar
Cell: 9840071715, Tamilnadu

Mr. D. R. Gahane
Cell: 98928 32289, Maharashtra

Mr. V. D. Dobarja
Cell: 98790 60666, Gujarat

Dr. A. Ramkishan
Cell: 63057 50926, CDSCO

Dr. Manish Kapoor
Cell: -9418081270 - Himachal Pradesh

Mrs. Kanchan Sinha
Cell: 9774548986 - Tripura

Joint Secretaries:

Mr. Rajkumar V. Zadbuke
Cell: 9892827738 - Maharashtra

Dr. S. Umesh
Cell: 94480 54321 - Karnataka

Mr. Pooran Chand
Cell: 9760366100 - Uttar Pradesh

Mrs. Dipika Chauhan
Cell: 7990351251 - Gujarat

Mr. Chandan Kumar Giri
Cell: 8895478543 - Odisha

Mr. Amit Kumar Bansal
Cell: 9198463261 - Uttar Pradesh

Mr. Biswajit Talukdar
Cell: 7086084833 - Assam

Treasurer:

Dr. Parmanand Verma
Cell: 9977177574 - Chhattisgarh

EC Members:

Dr. E. Ananda Kirouchenane
Cell: 9443959680 - Puducherry

Mr. Venkatesh Sinari
Cell: 9850608501 - Goa

Mrs. Garima Sharma
Cell: 9418086497 - Himachal Pradesh

Mr. M. N. Sridhar
Cell: 94441 17139 - Tamilnadu

Mr. Ashutosh Kumar Chaube
Cell: 9415632071 - Uttar Pradesh

Dr. Mahalakshmy .R
Cell: 9497004156 - Kerala

Dr. Zaffer Ahmad
Cell: 7298009092 - Jammu & Kashmir

Mr. Iarap T. D. Toi
Cell: 9233323204 - Meghalaya

Mr. Ibom Ete
Cell: 8414819858 - Arunachal Pradesh

Mr. Neeraj Kumar
Cell: 9458900286 - Uttarakhand

Dr. Mrinal Kanti Sarkar
Cell: 8974822360 - Tripura

Mr. Tapan Choudhry
Cell: 9230610226 - West Bengal

Date: 25 December 2025
Place: Ranchi, Jharkhand

The 11th day ceremony of Late Shri Amit Kumar, Drugs Inspector, Ranchi, Jharkhand, was attended today at his residence in Ranchi. On this solemn occasion, prayers were offered and heartfelt homage was paid to the departed soul.

As a gesture of solidarity and support, an amount of ₹50,000 (Rupees Fifty Thousand only) was handed over in cash to the bereaved parents towards funeral-related expenses.

Those present on the occasion were:

- Shri G. Koteswar Rao, National President
- Dr. Sujith Kumar, Joint Director, Drugs Control, Jharkhand
- Dr. Ramchandra Besra, President, DCOIWA Jharkhand
- Shri Pranav Prabhat, Secretary, DCOIWA Jharkhand
- Shri Amit Kumar, Assistant Director, Hazaribagh, Jharkhand

The gathering stood in silence and prayed for eternal peace to the departed soul and strength to the bereaved family to bear this irreparable loss.



H.Q. 15-21-150/6, New Balaji Nagar,
Kukatpally, Hyderabad (T.S), INDIA.
Phone : 8121296397, 8094357800, 9977177574.



DCOIWA Mission

To unite and organize the working and retired Drugs Control Officers from Indian States, Union Territories and CDSCO, with an object of coordinating their activities for establishment of social justice and regulating the relations of the officers with government agencies. Call : 8121296397, 8094357800,9977177574

- a) To unite and organize the working and retired Drugs Control Officers from Indian States, Union Territories and CDSCO, with an object of coordinating their activities for establishment of social justice and regulating the relations of the officers with government agencies.
- b) To safeguard and promote interest of its members all over the country
- c) To redress the grievances of the members.
- d) To promote a sense of fraternity, feeling of belonging and brotherhood amongst its members.
- e) To cooperate, accept affiliations and federate with the officers associations, federations, and confederations in the country where similar objectives are seen with international bodies.
- f) To achieve professional excellence through better coordination amongst its members.
- g) To offer better services to the public.
- h) To make dedicated efforts for welfare of its members.
- i) To conduct seminars, webinars, social activities, competitions, quiz programs etc. time to time.
- j) To take up any other activity conducive to the betterment in the discharge of their functions effectively and efficiently.

How to become a member

[Register Online](#)

[Download Form](#)

Dear Members,

As we conclude this edition of our e-newsletter, I would like to express my gratitude to our contributors and readers for their continued support. Your engagement is invaluable, and we appreciate the diverse perspectives that make our community thrive.

We strive to bring you relevant and insightful content, and we welcome any feedback or suggestions you may have for future editions. Our goal is to foster a collaborative space for knowledge-sharing among DCOIWA members, regulators, and pharmacy professionals.

Thank you for being a part of our community. We look forward to bringing you more enriching content in the upcoming editions.

Best regards,

Rakesh Dahiya
Editor-in-Chief
DCOIWA News



DISCLAIMER

This e-newsletter is released solely for educational and informational purposes, and is distributed free of charge to DCOIWA members, regulators, and pharmacy professionals. The content and opinions expressed in DCOIWA Newsletter are those of the authors of the particular article / research paper and do not necessarily reflect the views of DCOIWA or any its members. DCOIWA does not take any responsibility whatsoever for any inaccuracy thereto or loss caused therefrom. The editor and affiliated parties are not liable for any damages incurred as a result of the use of the contents of this newsletter. Material from DCOIWA Newsletter may be reproduced without permission provided the source is acknowledged.